日本臨牀　別冊　呼吸器症候群（第3版）　III

出版社： 日本臨牀社
発行日： 2021-10-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 呼吸器症候群（第3版）　III
電子書籍版： 2021-10-31 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　呼吸器症候群（第3版）　III
    　　　―その他の呼吸器疾患を含めて―

    VI．びまん性肺疾患
    　1．間質性肺炎
    　　（１）HTLV-1 associated bronchiolo-alveolar disorder（HABA)
    　　（２）Hermansky-Pudlak 症候群
    　　（３）RB-ILD
    　　（４）間質性肺炎の急性増悪
    　　（５）喫煙関連間質性肺疾患
    　　（６）急性間質性肺炎
    　　（７）巨細胞性間質性肺炎
    　　（８）膠原病肺
    　　（９）酸素性肺障害
    　　（10）造血幹細胞移植後の呼吸器合併症
    　　（11）造血幹細胞移植後の閉塞性細気管支炎
    　　（12）特発性間質性肺炎
    　　（13）特発性器質化肺炎
    　　（14）特発性肺線維症
    　　（15）剥離性間質性肺炎(DIP)
    　　（16）非特異性間質性肺炎
    　　（17）びまん性肺胞傷害
    　　（18）放射線肺障害
    　　（19）蜂巣肺
    　　（20）薬剤性間質性肺炎
    　　（21）リンパ球性間質性肺炎
    　2．肉芽腫性肺疾患
    　　（１）Löfgren症候群(急性サルコイドーシス)
    　　（２）好酸球性肉芽腫性多発血管炎
    　　（３）サルコイドーシス
    　　（４）肉芽腫性間質性肺炎
    　　（５）類上皮細胞肉芽腫
    　3．まれなびまん性肺疾患
    　　（１）結節性硬化症
    　　（２）自己免疫性肺胞タンパク症
    　　（３）続発性(二次性)肺胞タンパク症
    　　（４）肺胞出血
    　　（５）肺胞微石症
    　　（６）成人の肺ランゲルハンス細胞組織球症
    　　（７）びまん性肺石灰化症・転移性肺石灰化症
    　　（８）リンパ脈管筋腫症
    　4．じん肺および室内・大気環境汚染による肺疾患
    　　（１）Caplan症候群
    　　（２）Mixed dust pneumoconiosis(MDP)
    　　（３）珪肺の合併症
    　　（4）アルミニウム肺
    　　（5）い草染土じん肺
    　　（6）石綿肺
    　　（7）インジウム肺
    　　（8）加湿器肺
    　　（9）グラファイト肺症
    　　（10）珪肺症
    　　（11）人造鉱物繊維と肺疾患
    　　（12）タルク肺
    　　（13）炭坑夫肺
    　　（14）炭素系じん肺
    　　（15）超硬合金肺
    　　（17）パラコート肺
    　　（18）ベリリウム肺
    　　（19）溶接工肺
    　　（20）室内環境汚染による肺疾患
    　　（21）大気環境汚染による肺疾患

    VII．各種疾患にみられる呼吸器病変
    　１．自己免疫疾患
    　　（１）Goodpasture症候群
    　　（２）Sjogren 症候群
    　　（３）成人発症スチル病
    　　（４）強直性脊椎炎
    　　（５）混合性結合組織病(MCTD)の肺病変
    　　（６）全身性エリテマトーデス
    　　（７）全身性強皮症
    　　（８）多発性筋炎・皮膚筋炎に関わる呼吸器病変（間質性肺疾患を中心に）
    　　（９）関節リウマチ
    　　（10）IgG4関連疾患
    　　（11）IgA血管炎（Henoch-Schonlein 紫斑病）
    　２．造血器疾患
    　　（１）Bare lymphocyte 症候群
    　　（２）DIC
    　　（３）Polycythemia vera
    　　（４）赤芽球癆
    　　（５）クリオグロブリン血症
    　　（６）原発性マクログロブリン血症/リンパ形質細胞性リンパ腫
    　３．先天性(遺伝性)代謝疾患
    　　（１）先天性脂質代謝異常症
    　　（２）糖原病(グリコーゲン蓄積症)
    　　（３）ムコ多糖症

    VIII．その他
    　１．Morgagniヘルニア(胸骨後ヘルニア）
    　２．Recklinghausen病
    　３．Whipple病
    　４．悪性組織球症/組織球肉腫
    　５．炎症性気管支ポリープ
    　６．黄色爪症候群
    　７．原発性線毛機能不全症
    　８．術後急性肺障害
    　９．透過性亢進肺
    　10．粘液塞栓
    　11．ヒトアジュバント病

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

VI びまん性肺疾患

P.8 掲載の参考文献
1) Einsiedel L, et al : Human T-cell leukaemia virus type 1 associated pulmonary disease : clinical and pathological features of an under-recognised complication of HTLV-1 infection. Retrovirology 18 : 1, 2021.
 
2) Kimura I, et al : Presence of antibodies against adult T cell leukemia antigen in the patients with chronic respiratory diseases. Acta Med Okayama 40 : 281-284, 1986.
 
3) Vernant JC, et al : T-lymphocyte alveolitis, tropical spastic paresis, and Sjogren syndrome. Lancet 1 : 177, 1988.
PubMed
4) Sugimoto M, et al : Chronic bronchioloalveolitis associated with human T-cell lymphotrophic virus type I infection. Curr Opin Pulm Med 4 : 98-102, 1998.
 
5) Cho I, et al : In vivo proviral burden and viral RNA expression in T cell subsets of patients with human T lymphotropic virus type-1-associated myelopathy/tropical spastic paraparesis. Am J Trop Med Hyg 53 : 412-418, 1995.
 
6) Sugimoto M, et al : Pulmonary involvement in patients with HTLV-1-associated myelopathy : increased soluble IL-2 receptors in bronchoalveolar lavage fluid. Am Rev Respir Dis 139 : 1329-1335, 1989.
PubMed
7) Matsumoto M, et al : Spontaneous T cell proliferation and release of soluble interleukin-2 receptors in patients with HTLV-1-associated myelopathy. Am J Trop Med Hyg 42 : 365-373, 1990.
PubMed
8) Greene WC, et al : The human interleukin-2 receptor : normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med 105 : 560-572, 1986.
 
9) Nakagawa M, et al : HTLV-1-associated myelopathy : analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1 : 50-61, 1995.
PubMed
10) Okada F, et al : Pulmonary CT findings in 320 carriers of human T-lymphotropic virus type 1. Radiology 240 : 559-564, 2006.
PubMed
11) Yamashiro T, et al : CT scans of the chest in carriers of human T-cell lymphotropic virus type 1 : presence of interstitial pneumonia. Acad Radiol 19 : 952-957, 2012.
 
12) Kadota J, et al : Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis. Chest 125 : 1239-1247, 2004.
PubMed
13) 荒木潤, ほか : HTLV-1 associated myelopathy (HAM) にみられた肺病変の1例. 日本胸部疾患学会雑誌 27 : 1375-1379, 1989.
 
14) Einsiedel L, et al : Human T-Lymphotropic Virus type 1c subtype proviral loads, chronic lung disease and survival in a prospective cohort of Indigenous Australians. PLoS Negl Trop Dis 12 : e0006281, 2018.
 
15) 木村郁郎 : HABA (HTLV-I 関連細気管支肺胞異常症, HTLV-I associated bronchiolo-alveolar disorder). 日本胸部疾患学会雑誌 30 : 787-795, 1992.
 
P.13 掲載の参考文献
1) 難治性びまん性肺疾患診療の手引き (日本呼吸器学会監, 難治性びまん性肺疾患 診療の手引き作成委員会編), p72-98, 南江堂, 2017.
 
2) Velazquez-Diaz P, et al : Hermansky-Pudlak Syndrome and Lung Disease : Pathogenesis and Therapeutics. Front Pharmacol 12 : 644671, 2021.
PubMed
3) 海老名雅仁, 桑野和善 : 稀少難治性びまん性肺疾患分科会報告 Hermansky-Pudlak症候群関連 間質性肺炎に関する疫学調査. 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班 平成26年度研究報告書, p53-56, 2015.
 
4) O'Brien K, et al : Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 103 : 128-134, 2011.
PubMed
5) Meyer KC, Decker CA : Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag 13 : 427-437, 2017.
PubMed
6) O'Brien KJ, et al : Prolonged treatment with open-label pirfenidone in Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 125 : 168-173, 2018.
PubMed
7) El-Chemaly S, et al : The Immunome in Two Inherited Forms of Pulmonary Fibrosis. Front Immunol 9 : 76, 2018.
PubMed
8) El-Chemaly S, et al : Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. PLoS One 13 : e0194193, 2018.
PubMed
9) El-Chemaly S, Young LR : Hermansky-Pudlak Syndrome. Clin Chest Med 37 : 505-511, 2016.
PubMed
P.18 掲載の参考文献
1) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
2) Niewoehner DE, et al : Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 291 : 755-758, 1974.
PubMed
3) Myers JL, et al : Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis 135 : 880-884, 1987.
PubMed
4) Yousem SA, et al : Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 64 : 1373-1380, 1989.
PubMed
5) American Thoracic Society, et al : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165 : 277-304, 2002.
PubMed
6) Karakatsani A, et al : Epidemiology of interstitial lung diseases in Greece. Respir Med 103 : 1122-1129, 2009.
PubMed
7) Vassallo R, et al : The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis : high-resolution CT, histologic, and functional correlations. Chest 124 : 1199-1205, 2003.
PubMed
8) Portnoy J, et al : Respiratory bronchiolitis-interstitial lung disease : long-term outcome. Chest 131 : 664-671, 2007.
PubMed
9) Yamada Y, et al : The clinical and bronchoalveolar lavage features of respiratory bronchiolitis-associated interstitial lung disease. J Bronchol 11 : 160-164, 2004.
 
10) Park JS, et al : Respiratory bronchiolitis-associated interstitial lung disease : radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr 26 : 13-20, 2002.
PubMed
11) Remy-Jardin M, et al : Lung parenchymal changes secondary to cigarette smoking : pathologic-CT correlations. Radiology 186 : 643-651, 1993.
PubMed
12) Fraig M, et al : Respiratory bronchiolitis : a clinicopathologic study in current smokers, exsmokers, and never-smokers. Am J Surg Pathol 26 : 647-653, 2002.
PubMed
13) Yousem SA : Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia : a proposal. Mod Pathol 19 : 1474-1479, 2006.
 
14) Scheidl SJ, et al : Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies : A Retrospective Analysis of a Large Austrian Registry. Respiration 91 : 26-33, 2016.
PubMed
15) Yamada Y, et al : Respiratory bronchiolitis and lung carcinoma. Respir Investig 51 : 184-190, 2013.
PubMed
P.23 掲載の参考文献
1) Kondoh Y, et al : Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103 : 1808-1812, 1993.
PubMed
2) 特発性間質性肺炎 診断と治療の手引き [改訂第3版] (日本呼吸器学会 びまん性肺疾患診断・治療ガイドライン作成委員会編), 南江堂, 2016.
 
3) Kolb M, et al : Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 27 : 180071, 2018.
PubMed
4) Suzuki A, et al : Acute exacerbations of fibrotic interstitial lung diseases. Respirology 25 : 525-534, 2020.
PubMed
5) Collard HR, et al : Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 194 : 265-275, 2016.
 
6) Kreuter M, et al : Acute exacerbation of idiopathic pulmonary fibrosis : international survey and call for harmonisation. Eur Respir J 55 : 1901760, 2020.
PubMed
7) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
8) Natsuizaka M, et al : Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190 : 773-779, 2014.
PubMed
9) Bando M, et al : Infection of TT virus in patients with idiopathic pulmonary fibrosis. Respir Med 95 : 935-942, 2001.
PubMed
10) Wootton SC, et al : Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183 : 1698-1702, 2011.
PubMed
11) Sheng G, et al : Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis : A Meta-Analysis. Chest 157 : 1175-1187, 2020.
PubMed
12) Collard HR, et al : Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 : 636-643, 2007.
PubMed
13) Richeldi L, et al : Nintedanib in patients with idiopathic pulmonary fibrosis : Combined evidence from the TOMORROW and INPULSISO trials. Respir Med 113 : 74-79, 2016.
PubMed
14) Kang J, et al : Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis : a propensity score matching analysis. Sci Rep 10 : 15620, 2020.
PubMed
15) 特発性肺線維症の治療ガイドライン 2017 (厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班 特発性肺線維症の治療ガイドライン作成委員会編), 南江堂, 2017.
 
16) Farrand E, et al : Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology 25 : 629-635, 2020.
 
17) Hozumi H, et al : Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis : A propensity score-matched analysis. Respirology 24 : 792-798, 2019.
PubMed
18) Kondoh Y, et al : Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med 201 : 1110-1119, 2020.
PubMed
19) Raghu G, et al : An official ATS/ERS/JRS/ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 : 788-824, 2011.
PubMed
P.29 掲載の参考文献
1) Cottin V, et al : Combined pulmonary fibrosis and emphysema : a distinct underrecognised entity. Eur Respir J 26 : 586-593, 2005.
PubMed
2) Kawabata Y, et al : Smoking-related changes in the background lung of specimens resected for lung cancer : a semiquantitative study with correlation to postoperative course. Histopathology 53 : 707-714, 2008.
PubMed
3) Katzenstein AL, et al : Clinically occult interstitial fibrosis in smokers : classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol 41 : 316-325, 2010.
PubMed
4) Colby TV : Bronchiolitis. Pathologic considerations. Am J Clin Pathol 109 : 101-109, 1998.
PubMed
5) Moon J, et al : Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax 54 : 1009-1014, 1999.
PubMed
6) Ryu JH, et al : Smoking-related interstitial lung diseases : a concise review. Eur Respir J 17 : 122-132, 2001.
PubMed
7) Vassallo R, et al : The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis : high-resolution CT, histologic, and functional correlations. Chest 124 : 1199-1205, 2003.
PubMed
8) Alder JK, et al : Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 184 : 904-912, 2011.
PubMed
9) Niewoehner DE, et al : Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 291 : 755-758, 1974.
PubMed
10) Yousem SA, et al : Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 64 : 1373-1380, 1989.
PubMed
11) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
12) Roden AC, et al : BRAF V600E expression in Langerhans cell histiocytosis : clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 38 : 548-551, 2014.
 
13) Harari S, et al : Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med 106 : 1286-1292, 2012.
PubMed
14) Reddy TL, et al : Respiratory bronchiolitis with fibrosis. High-resolution computed tomography findings and correlation with pathology. Ann Am Thorac Soc 10 : 590-601, 2013.
PubMed
P.34 掲載の参考文献
1) Katzenstein AL, et al : Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 10 : 256-267, 1986.
PubMed
2) Hamman L, Rich AR : Fulminating Diffuse Interstitial Fibrosis of the Lungs. Trans Am Clin Climatol Assoc 51 : 154-163, 1935.
PubMed
3) Askin FB : Back to the future : the Hamman-Rich syndrome and acute interstitial pneumonia. Mayo Clin Proc 65 : 1624-1626, 1990.
 
4) Olson J, et al : Hamman-Rich syndrome revisited. Mayo Clin Proc 65 : 1538-1548, 1990.
PubMed
5) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
6) Katzenstein AL, Myers JL : Idiopathic pulmonary fibrosis : clinical relevance of pathologic classification. Am J Respir Crit Care Med 157 : 1301-1315, 1998.
PubMed
7) Vourlekis JS : Acute interstitial pneumonia. Clin Chest Med 25 : 739-747, vii, 2004.
PubMed
8) American Thoracic Society, et al : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165 : 277-304, 2002.
PubMed
9) Bonaccorsi A, et al : Acute interstitial pneumonia : report of a series. Eur Respir J 21 : 187-191, 2003.
PubMed
10) Ichikado K, et al : Acute interstitial pneumonia : high-resolution CT findings correlated with pathology. AJR Am J Roentgenol 168 : 333-338, 1997.
PubMed
11) Ichikado K, et al : Acute interstitial pneumonia : comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 165 : 1551-1556, 2002.
PubMed
12) 急性間質性肺炎 (AIP). 特発性間質性肺炎 診断と治療の手引き [改訂第3版] (日本呼吸器学会 びまん性肺疾患診断・治療ガイドライン作成委員会編), p83-87, 南江堂, 2016.
 
13) Vourlekis JS, et al : Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore) 79 : 369-378, 2000,
PubMed
14) Suh GY, et al : Early intervention can improve clinical outcome of acute interstitial pneumonia. Chest 129 : 753-761, 2006.
PubMed
15) Quefatieh A, et al : Low hospital mortality in patients with acute interstitial pneumonia. Chest 124 : 554-559, 2003.
PubMed
P.38 掲載の参考文献
1) Liebow AA : New concepts and entities in pulmonary disease. In : The Lung (ed by Liebow AA, Smith DE), p332-365, Williams & Wilkins, Baltimore, 1968.
 
2) Abraham JL, et al : Development and use of a pneumoconiosis database of human pulmonary inorganic particulate burden in over 4001ungs. Scanning Microsc 5 : 95-104 ; discussion 105-108, 1991.
 
3) Demedts M, et al : Cobalt lung in diamond polishers. Am Rev Respir Dis 130 : 130-135, 1984.
PubMed
4) Paris C, et al : Giant cell interstitial pneumonia : report of two cases with high titanium concentration in the lung. Am J Respir Crit Care Med 184 : 1315-1317, 2011.
PubMed
5) Sarwate M, et al : Unusual pneumoconiosis in two patients with heavy print toner, and paper dust exposure. Am J Ind Med 63 : 821-827, 2020.
PubMed
6) Khoor A, et al : Giant cell interstitial pneumonia in patients without hard metal exposure : analysis of 3 cases and review of the literature. Hum Pathol 50 : 176-182, 2016.
PubMed
7) Menon B, et al : Giant cell interstitial pneumonia in a 60-year-old female without hard metal exposure. Respiration 73 : 833-835, 2006.
 
8) Moriyama H, et al : Two-dimensional analysis of elements and mononuclear cells in hard metal lung disease. Am J Respir Crit Care Med 176 : 70-77, 2007.
PubMed
9) Mizutani RF, et al : Hard metal lung disease : a case series. J Bras Pneumol 42 : 447-452, 2016.
 
10) Naqvi AH, et al : Pathologic spectrum and lung dust burden in giant cell interstitial pneumonia (hard metal disease/cobalt pneumonitis) : review of 100 cases. Arch Environ Occup Health 63 : 51-70, 2008.
PubMed
11) Tanaka J, et al : An observational study of giant cell interstitial pneumonia and lung fibrosis in hard metal lung disease. BMJ Open 4 : e004407, 2014.
PubMed
12) Choi JW, et al : Giant cell interstitial pneumonia : high-resolution CT and pathologic findings in four adult patients. AJR Am J Roentgenol 184 : 268-272, 2005.
PubMed
13) Chiarchiaro J, et al : A case series describing common radiographic and pathologic patterns of hard metal pneumoconiosis. Respir Med Case Rep 25 : 124-128, 2018.
PubMed
14) 岡本賢三 : 超硬合金肺の病理像の特徴. 日本胸部臨床 70 : 1238-1248, 2011.
Medical*Online
15) 清家正博, ほか : 超硬合金労働者に発症したCA19-9が著明な高値を示した巨細胞性間質性肺炎の1例. 日本胸部疾患学会雑誌 33 : 894-899, 1995.
 
P.44 掲載の参考文献
1) Fischer A, et al : An official European Respiratory Society/American Thoracic Society research statement : interstitial pneumonia with autoimmune features. Eur Respir J 46 : 976-987, 2015.
PubMed
2) Nakashima R, et al : The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One 9 : e85062, 2014.
PubMed
3) Sato S, et al : Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS One 11 : e0154285, 2016.
PubMed
4) 膠原病に伴う間質性肺疾患 診断・治療指針 2020 (日本呼吸器学会・日本リウマチ学会合同膠原病に伴う間質性肺疾患 診断・治療指針2020作成委員会編), 日本呼吸器学会, 2020.
 
5) Tashkin DP, et al : Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 : 2655-2666, 2006.
PubMed
6) Hoyles RK et al : A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 : 3962-3970, 2006.
PubMed
7) Tashkin DP, et al : Mycophenolate mofetil versus oral cyclophosphamide in sclerodermarelated interstitial lung disease (SLS II) : a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4 : 708-719, 2016.
 
8) Distler O, et al : Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 380 : 2518-2528, 2019.
PubMed
9) Khanna D, et al : Tocilizumab in systemic sclerosis : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8 : 963-974, 2020.
PubMed
10) Sullivan KM, et al : Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 378 : 1066-1067, 2018.
PubMed
11) Goh NS, et al : Interstitial lung disease in systemic sclerosis : a simple staging system. Am J Respir Crit Care Med 177 : 1248-1254, 2008.
PubMed
12) Winstone TA, et al : Predictors of mortality and progression in scleroderma-associated interstitial lung disease : a systematic review. Chest 146 : 422-436, 2014.
PubMed
13) Bouros D, et al : Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 : 1581-1586, 2002.
PubMed
14) Jacob J, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 53 : 1800869, 2019.
PubMed
15) Wells AU, et al : Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial : a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8 : 453-460, 2020.
 
16) Vicente-Rabaneda EF, et al : Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis : A systematic literature review. Autoimmun Rev 20 : 102830, 2021.
PubMed
17) Wijsenbeek M, Cottin V : Spectrum of Fibrotic Lung Diseases. N Engl J Med 383 : 958-968, 2020.
PubMed
18) Koduri G, et al : Interstitial lung disease has a poor prognosis in rheumatoid arthritis : results from an inception cohort. Rheumatology (Oxford) 49 : 1483-1489, 2010.
 
19) Bongartz T, et al : Incidence and mortality of interstitial lung disease in rheumatoid arthritis : a population-based study. Arthritis Rheum 62 : 1583-1591, 2010.
PubMed
20) Park JH, et al : Prognosis of fibrotic interstitial pneumonia : idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175 : 705-711, 2007.
PubMed
21) Kim EJ, et al : Rheumatoid arthritis-associated interstitial lung disease : the relevance of histopathologic and radiographic pattern. Chest 136 : 1397-1405, 2009.
PubMed
22) Tsuchiya Y, et al : Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37 : 1411-1417, 2011.
PubMed
23) Suda T, et al : Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103 : 846-853, 2009.
PubMed
24) Chen Z, et al : Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med 381 : 291-293, 2019.
PubMed
25) Shirakashi M, et al : Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford) 59 : 3284-3292, 2020.
PubMed
26) Hozumi H, et al : Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease : A Propensity Score-matched Analysis. J Rheumatol 46 : 509-517, 2019.
PubMed
27) Fujisawa T, et al : Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32 : 58-64, 2005.
PubMed
28) Gono T, et al : Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49 : 1354-1360, 2010.
PubMed
29) Hozumi H, et al : Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease : a retrospective case control study. PLoS One 10 : e0120313, 2015.
PubMed
30) Enomoto N, et al : Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. Thorax, 2021. (DOI : 10.1136/thoraxjnl-2020-216263)
 
31) Fischer A, du Bois R : Interstitial lung disease in connective tissue disorders. Lancet 380 : 689-698, 2012.
PubMed
P.50 掲載の参考文献
1) 安井修司 : 酸素中毒. 呼吸 19 : 129-137, 2000.
Medical*Online
2) 松田範子 : 酸素中毒における遅延因子と促進因子. 日本高気圧環境医学会雑誌 31 : 175-180, 1996.
Medical*Online
3) Warren JS, et al : Consequences of Oxidant Injury. In : The Lung : Scientific Foundations (ed by Crystal RG, West JB), p1829-1838, Raven Press, New York, 1991.
 
4) Beers MF : Oxygen Therapy and Pulmonary Oxygen Toxicity. In : Fishman's Pulmonary Diseases and Disorders, 4th ed (ed by Fishman AP), p2613-2630, McGraw-Hill, New York, 2008.
 
5) ARDS診療ガイドライン 2016 (Part 1) (3学会合同ARDS診療ガイドライン2016作成委員会編), p54, 日本呼吸器学会, 2016.
 
6) White CW, et al : Transgenic mice with expression of elevated levels of copper-zinc superoxide dismutase in the lungs are resistant to pulmonary oxygen toxicity. J Clin Invest 87 : 2162-2168, 1991.
PubMed
7) Welty-Wolf KE, et al : Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. II. Morphometric analysis. J Appl Physiol (1985) 83 : 559-568, 1997.
PubMed
8) Waxman AB, et al : Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest 101 : 1970-1982, 1998.
PubMed
P.55 掲載の参考文献
1) ありがとう!! 非血縁者間造血幹細胞移植 累計症例4万例突破! (日本赤十字社, 日本骨髄バンク Press Release), 2019. [https://www.jmdp.or.jp/documents/file/07_about_us/press/press_19_03_22.pdf] (2021年8月閲覧)
 
2) Azoulay E, et al : Acute respiratory failure in immunocompromised adults. Lancet Respir Med 7 : 173-186, 2019.
PubMed
3) Lucena CM, et al : Pulmonary complications in hematopoietic SCT : a prospective study. Bone Marrow Transplant 49 : 1293-1299, 2014.
PubMed
4) Haider S, et al : Noninfectious pulmonary complications of haematopoietic stem cell transplantation. Eur Respir Rev 29 : 190119, 2020.
PubMed
5) 造血細胞移植ガイドライン 造血細胞移植後の感染管理 [第4版] (平成28学会年度日本造血細胞移植学会ガイドライン委員会編), 日本造血細胞移植学会, 2017.
 
6) Kontoyiannis DP, et al : Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006 : overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50 : 1091-1100, 2010.
PubMed
7) 造血細胞移植ガイドライン 真菌感染症の予防と治療 (平成28学会年度日本造血細胞移植学会ガイドライン委員会編), 日本造血細胞移植学会, 2017.
 
8) Zhang Z, et al : Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest 159 : 2325-2333, 2021.
PubMed
9) 造血細胞移植ガイドライン ウイルス感染症の予防と治療 サイトメガロウイルス感染症 [第4版] (平成30学会年度日本造血細胞移植学会ガイドライン委員会編), 日本造血細胞移植学会, 2018.
 
10) Soubani AO, Uberti JP : Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J 29 : 1007-1019, 2007.
PubMed
11) 造血細胞移植ガイドライン GVHD [第4版] (平成30学会年度日本造血細胞移植学会ガイドライン委員会編), 日本造血細胞移植学会, 2018.
 
12) 難治性びまん性肺疾患 診療の手引き (日本呼吸器学会監, 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班 難治性びまん性肺疾患診療の手引き作成委員会編), 南江堂, 2017.
 
13) Homma S, et al : Intractable diffuse pulmonary diseases : Manual for diagnosis and treatment. Respir Investig 59 : 8-33, 2021.
PubMed
14) Bergeron A, et al : Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J 51 : 1702617, 2018.
PubMed
P.58 掲載の参考文献
1) 難治性びまん性肺疾患 診療の手引き (日本呼吸器学会監, 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班 難治性びまん性肺疾患診療の手引き作成委員会編), 南江堂, 2017.
 
2) Soubani AO, Uberti JP : Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J 29 : 1007-1019, 2007.
PubMed
3) Stewart S, et al : Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 26 : 1229-1242, 2007.
PubMed
4) Meyer KC, et al : An international ISHLT/ATS/ERS clinical practice guideline : diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 44 : 1479-1503, 2014.
PubMed
5) Bergeron A, et al : Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J 51 : 1702617, 2018.
PubMed
6) Homma S, et al : Intractable diffuse pulmonary diseases : Manual for diagnosis and treatment. Respir Investig 59 : 8-33, 2021.
PubMed
7) Haider S, et al : Noninfectious pulmonary complications of haematopoietic stem cell transplantation. Eur Respir Rev 29 : 190119, 2020.
PubMed
8) Hasegawa Y, et al : Perfusion and ventilation isotope lung scans in constrictive bronchiolitis obliterans. A series of three cases. Respiration 69 : 550-555, 2002.
PubMed
9) Lee ES, et al : Early bronchiolitis obliterans following lung transplantation : accuracy of expiratory thin-section CT for diagnosis. Radiology 216 : 472-477, 2000.
PubMed
10) Zheng L, et al : Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax 55 : 53-59, 2000.
PubMed
11) Slebos DJ, et al : Longitudinal profile of bronchoalveolar lavage cell characteristics in patients with a good outcome after lung transplantation. Am J Respir Crit Care Med 165 : 501-507, 2002.
PubMed
12) Vanaudenaerde BM, et al : Broncho-alveolar lavage fluid recovery correlates with airway neutrophilia in lung transplant patients. Respir Med 102 : 339-347, 2008.
PubMed
13) Kim SW, et al : Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Respir Res 17 : 63, 2016.
 
14) Williams KM, et al : Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22 : 710-716, 2016.
PubMed
15) Bergeron A, et al : Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant : The ALLOZITHRO Randomized Clinical Trial. JAMA 318 : 557-566, 2017.
PubMed
P.64 掲載の参考文献
1) 間質性肺疾患診療マニュアル [改訂第3版] (久保恵嗣監, 藤田次郎, 喜舎場朝雄編), 南江堂, 2020.
 
2) 膠原病に伴う間質性肺疾患 診断・治療指針 2020 (日本呼吸器学会・日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針作成委員会編), 日本呼吸器学会, 2020.
 
3) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
4) 特発性間質性肺炎診断と治療の手引き [改訂第3版] (日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編), 南江堂, 2016.
 
5) Raghu G, et al : Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198 : e44-e68, 2018.
PubMed
6) Lentz RJ, et al : Transbronchial cryobiopsy for diffuse parenchymal lung disease : a state-of-the-art review of procedural techniques, current evidence, and future challenges. J Thorac Dis 9 : 2186-2203, 2017.
PubMed
7) Ravaglia C, et al : Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases : a large cohort of 699 patients. BMC Pulm Med 19 : 16, 2019.
 
8) Tomassetti S, et al : Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis : a retrospective validation study. Lancet Respir Med 8 : 786-794, 2020.
PubMed
9) Troy LK, et al : Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE) : a prospective, comparative study. Lancet Respir Med 8 : 171-181, 2020.
PubMed
10) Raghu G, et al : An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline : Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192 : e3-19, 2015.
PubMed
11) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
P.69 掲載の参考文献
1) Davison AG, et al : Cryptogenic organizing Pneumonitis. Q J Med 52 : 382-394, 1983.
PubMed
2) Epler GR, et al : Bronchiolitis obliterans organizing pneumonia. N Engl J Med 312 : 152-158, 1985.
PubMed
3) American Thoracic Society, European Respiratory Society : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165 : 277-304, 2002.
PubMed
4) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
5) 特発性間質性肺炎診断と治療の手引き (日本呼吸器学会びまん性肺疾患, 診断・治療ガイドライン作成委員会編), 南江堂, 2004.
 
6) Gudmundsson G, et al : Epidemiology of organising pneumonia in Iceland. Thorax 61 : 805-808, 2006.
PubMed
7) 中山智子, 福田悠 : 線維化の病理・病態. 日本胸部臨床 62 (増刊) : S140-S146, 2003.
Medical*Online
8) Akira M, et al : Bronchiolitis obliterans organizing pneumonia manifesting as multiple large nodules or masses. AJR Am J Roentgenol 170 : 291-295, 1998.
PubMed
9) Poletti V, et al : The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing Pneumonia. Eur Respir J 9 : 2513-2516, 1996.
PubMed
10) Beasley MB, et al : Acute fibrinous and organizing pneumonia : ahistological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 126 : 1064-1070, 2002.
 
11) Stover DE, Mangino D : Macrolides : a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest 128 : 3611-3617, 2005.
PubMed
12) Bradley B, et al : Interstitial lung disease guideline : the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63 (Suppl 5) : v1-58, 2008.
 
13) Shitenberg D, et al : Successful Rituximab Therapy in Steroid-Resistant, Cryptogenic Organizing Pneumonia : A Case Series. Respiration 90 : 155-159, 2015.
PubMed
14) Lazor R, et al : Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM "O" P). Am J Respir Crit Care Med 162 : 571-577, 2000.
 
15) Saito Z, et al : Predictive factors for relapse of cryptogenic organizing pneumonia. BMC Pulm Med 19 : 10, 2019.
 
P.75 掲載の参考文献
1) Katoh T, et al : A rapidly progressive case of interstitial pneumonia. Intern Med 34 : 388-392, 1995.
 
2) 特発性間質性肺炎診断と治療の手引き [改訂第3版] (日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編), 南江堂, 2016.
 
3) Natsuizaka M, et al : Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190 : 773-779, 2014.
PubMed
4) Raghu G, et al : Diagnosis of ldiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198 : e44-e68, 2018.
 
5) Yokoyama A, et al : Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11 : 164-168, 2006.
PubMed
6) Takahashi H, et al : Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 162 : 1109-1114, 2000.
 
7) King TE, et al : A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 : 2083-2092, 2014.
PubMed
8) Richeldi L, et al : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 : 2071-2082, 2014.
PubMed
9) Raghu G, et al : An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline : Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192 : e3-19, 2015.
PubMed
10) 特発性肺線維症の治療ガイドライン 2017 (厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班 特発性肺線維症の治療ガイドライン作成委員会編), 南江堂, 2017.
 
11) Homma S, et al : Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig 56 : 268-291, 2018.
PubMed
12) Kondoh Y, et al : Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103 : 1808-1812, 1993.
PubMed
P.79 掲載の参考文献
1) Liebow AA, et al : Desquamative Interstitial Pneumonia. Am J Med 39 : 369-404, 1965.
PubMed
2) Liebow AA : New concepts and entities in pulmonary disease. In : The Lung (ed by Liebow AA, Smith DE), p332-365, Williams & Wilkins, Baltimore, 1968.
 
3) van Furth R, et al : The mononuclear phagocyte system : a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ 46 : 845-852, 1972.
PubMed
4) Corrin B, Price AB : Electron microscopic studies in desquamative interstitial pneumonia associated with asbestos. Thorax 27 : 324-331, 1972.
PubMed
5) Carrington CB, et al : Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 298 : 801-809, 1978.
PubMed
6) Myers JL, et al : Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis 135 : 880-884, 1987.
PubMed
7) American Thoracic Society, et al : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165 : 277-304, 2002.
PubMed
8) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
9) Myers JL : Idiopathic interstitial pneumonias. In : Thurlbeck's Pathology of the Lung, 3rd ed (ed by Churg AM, et al), p563-600, Thieme, New York, 2005.
 
10) King MB, et al : Recurrence of desquamative interstitial pneumonia after lung transplantation. Am J Respir Crit Care Med 156 : 2003-2005, 1997.
PubMed
11) Wesselius LJ, et al : Alveolar macrophage content of isoferritins and transferrin. Comparison of nonsmokers and smokers with and without chronic airflow obstruction. Am Rev Respir Dis 145 : 311-316, 1992.
PubMed
12) Katzenstein AL : Desquamative interstitial pneumonia/respiratory bronchiolitis interstitial lung disease. In : Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease, 4th ed, p61-66, WB Saunders, Philadelphia, 2006.
 
13) 北市正則, 盧美淑 : びまん性線維化肺疾患の新しい分類 : 特発性間質性肺炎の病理組織所見, ATS/ERS国際分類 (2002) について. 綜合臨牀 52 : 1830-1842, 2003.
 
14) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
15) Hellemons ME, et al : Desquamative interstitial pneumonia : a systematic review of its features and outcomes. Eur Respir Rev 29 : 190181, 2020.
PubMed
P.84 掲載の参考文献
1) American Thoracic Society, European Respiratory Society : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165 : 277-304, 2002.
PubMed
2) Katzenstein AL, Fiorelli RF : Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 18 : 136-147, 1994.
PubMed
3) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
4) Travis WD, et al : Idiopathic nonspecific interstitial pneumonia : report of an American Thoracic Society project. Am J Respir Crit Care Med 177 : 1338-1347, 2008.
PubMed
5) Kinder BW, et al : Idiopathic nonspecific interstitial pneumonia : lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 176 : 691-697, 2007.
PubMed
6) Yamakawa H, et al : Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia. Respirology 23 : 1032-1040, 2018.
PubMed
7) Brown KK, et al : The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 55 : 2000085, 2020.
PubMed
8) Wells AU, et al : Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial : a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8 : 453-460, 2020.
 
P.89 掲載の参考文献
1) Katzenstein AL, et al : Diffuse alveolar damage-the role of oxygen, shock, and related factors. A review. Am J Pathol 85 : 209-228, 1976.
PubMed
2) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
3) Hamman L, Rich AR : Fulminating Diffuse Interstitial Fibrosis of the Lungs. Trans Am Clin Climatol Assoc 51 : 154-163, 1935.
PubMed
4) Olson J, et al : Hamman-Rich syndrome revisited. Mayo Clin Proc 65 : 1538-1548, 1990.
PubMed
5) 特発性間質性肺炎診断と治療の手引き [改訂第3版] (日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編), 南江堂, 2016.
 
6) Xu Z, et al : Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8 : 420-422, 2020.
PubMed
7) Ware LB, Matthay MA : The acute respiratory distress syndrome. N Engl J Med 342 : 1334-1349, 2000.
PubMed
8) Katzenstein AL, Myers JL : Idiopathic pulmonary fibrosis : clinical relevance of pathologic classification. Am J Respir Crit Care Med 157 : 1301-1315, 1998.
PubMed
9) Polak SB, et al : A systematic review of pathological findings in COVID-19 : a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol 33 : 2128-2138, 2020.
PubMed
10) Konopka KE, et al : Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD. Histopathology 77 : 570-578, 2020.
PubMed
11) Ichikado K et al : Acute interstitial pneumonia : high-resolution CT findings correlated with pathology. AJR Am J Roentgenol 168 : 333-338, 1997.
PubMed
12) Johkoh T, et al : Acute interstitial pneumonia : thin-section CT findings in 36 patients. Radiology 211 : 859-863, 1999.
PubMed
13) Suzuki A, et al : Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis. Respir Med Case Rep 19 : 5-8, 2016.
 
14) Enomoto N, et al : Analysis of systemic lupus erythematosus-related interstitial pneumonia : a retrospective multicentre study. Sci Rep 9 : 7355, 2019.
PubMed
15) ARDS Definition Task Force ; Ranieri VM, et al : Acute respiratory distress syndrome : the Berlin Definition. JAMA 307 : 2526-2533, 2012.
PubMed
16) Esteban A, et al : Evolution of mortality over time in patients receiving mechanical ventilation. Am J Respir Crit Care Med 188 : 220-230, 2013.
PubMed
17) Ike JD, et al : The Association Between Acute Respiratory Distress Syndrome Hospital Case Volume and Mortality in a U. S. Cohort, 2002-2011. Crit Care Med 46 : 764-773, 2018.
 
P.94 掲載の参考文献
1) Crestani B, et al : Migratory bronchiolitis obliterans organizing pneumonia after unilaterai radiation therapy for breast carcinoma. Eur Respir J 8 : 318-321, 1995.
PubMed
2) Bayle JY, et al : Migratory organizing pneumonitis "primed" by radiation therapy. Eur Respir J 8 : 322-326, 1995.
PubMed
3) Epler GR, Kelly EM : Post-Breast Cancer Radiotherapy Bronchiolitis Obliterans Organizing Pneumonia. Respir Care 65 : 686-692, 2020.
PubMed
4) Roy S, et al : Biology of Radiation-Induced Lung Injury. Semin Radiat Oncol 31 : 155-161, 2021.
PubMed
5) Hanania AN, et al : Radiation-Induced Lung Injury : Assessment and Management. Chest 156 : 150-162, 2019.
PubMed
6) Hagiwara Y, et al : Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease. J Radiat Res 61 : 563-574, 2020.
PubMed
7) Kohno N, et al : Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest 102 : 117-122, 1992.
PubMed
8) Takahashi H, et al : Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur Respir J 17 : 481-487, 2001.
 
9) Arroyo-Hernandez M, et al : Radiation-induced lung injury : current evidence. BMC Pulm Med 21 : 9, 2021.
PubMed
10) Choi YW, et al : Effects of radiation therapy on the lung : radiologic appearances and differential diagnosis. Radiographics 24 : 985-997 ; discussion 998, 2004.
PubMed
11) 特発性間質性肺炎診断と治療の手引き (改訂第4版) (日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編), 南江堂 (印刷中).
 
12) De Ruysscher D, et al : Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging : A preclinical study with a high precision image-guided irradiator. Radiother Oncol 124 : 482-487, 2017.
PubMed
13) Simone NL, et al : Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy : a pilot study. Radiat Oncol 2 : 19, 2007.
 
P.100 掲載の参考文献
1) Katzenstein A-LA : Honeycomb lung. In : Katzenstein and Askin's Surgical Pathology of Nonneoplastic Lung Disease, 3rd ed (ed by Katzenstein A-LA, et al), p76-79, WB Saunders, Philadelphia, 1997.
 
2) 福田悠 : 蜂巣肺. 病理と臨床 28 (臨時増刊号) : 24-25, 2010.
 
3) Hansell DM, et al : Fleischner Society : glossary of terms for thoracic imaging. Radiology 246 : 697-722, 2008.
PubMed
4) Raghu G, et al : Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198 : e44-e68, 2018.
PubMed
5) Coon DR, et al : Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. Exp Mol Pathol 80 : 119-123, 2006.
PubMed
6) Okudela K, et al : A subpopulation of airway epithelial cells that express hepatocyte nuclear factor 4α-its implication in the development of non-terminal respiratory unit-type lung adenocarcinoma. Histol Histopathol 34 : 1217-1227, 2019.
 
7) Cottin V, et al : Combined pulmonary fibrosis and emphysema : a distinct underrecognised entity. Eur Respir J 26 : 586-593, 2005.
PubMed
8) Kawabata Y, et al : Smoking-related changes in the background lung of specimens resected for lung cancer : a semiquantitative study with correlation to postoperative course. Histopathology 53 : 707-714, 2008.
PubMed
9) 武村民子 : 関節リウマチの慢性線維化肺における細気管支病変の関与 病理学的検討. 日本胸部臨床 75 : 1350-1362, 2016.
Medical*Online
10) Barcia SM, et al : Pulmonary interstitial emphysema in adults : a clinicopathologic study of 53 lung explants. Am J Surg Pathol 38 : 339-345, 2014.
PubMed
11) Tachibana Y, et al : Pulmonary interstitial emphysema is a risk factor for poor prognosis and a cause of air leaks. Respir Investig 57 : 444-450, 2019.
 
P.107 掲載の参考文献
1) 堀益靖, 服部登 : 薬剤性間質性肺炎. 日本内科学会雑誌 110 : 1099-1105, 2021.
 
2) Matsuno O : Drug-induced interstitial lung disease : mechanisms and best diagnostic approaches. Respir Res 13 : 39, 2012.
PubMed
3) 薬剤性肺障害の診断・治療の手引き [第2版] 2018 (日本呼吸器学会薬剤性肺障害の診断・治療の手引き第2版作成委員会編), メディカルレビュー社, 2018.
 
4) Shi L, et al : Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer : a systematic review and meta-analysis of clinical trials. Lung Cancer 83 : 231-239, 2014.
PubMed
5) Camus P, et al : Interstitial lung disease induced by drugs and radiation. Respiration 71 : 301-326, 2004.
PubMed
6) 近藤有好 : 薬剤による肺障害 (薬剤肺炎). 結核 74 : 33-41, 1999.
 
P.111 掲載の参考文献
1) Liebow AA, Carrington CB : The interstitial pneumonias. In : Frontiers of Pulmonary Radiology, 1st ed (ed by Simon M, et al), p102-141, Grune & Stratton, New York, 1969.
 
2) Travis WD, et al : An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 : 733-748, 2013.
PubMed
3) Chartrand S, et al : Clinical features and natural history of interstitial pneumonia with autoimmune features : A single center experience. Respir Med 119 : 150-154, 2016.
PubMed
4) Ahmad K, et al : Interstitial pneumonia with autoimmune features : Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 123 : 56-62, 2017.
 
5) Sambataro G, et al : Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. Respir Med 150 : 154-160, 2019.
PubMed
6) Cha SI, et al : Lymphoid interstitial pneumonia : clinical features, associations and prognosis. Eur Respir J 28 : 364-369, 2006.
PubMed
7) Swigris JJ, et al : Lymphoid interstitial pneumonia : a narrative review. Chest 122 : 2150-2164, 2002.
PubMed
8) Setoguchi Y, et al : Detection of human T-cell lymphotropic virus type I-related antibodies in patients with lymphocytic interstitial pneumonia. Am Rev Respir Dis 144 : 1361-1365, 1991.
PubMed
9) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165 : 277-304, 2002.
PubMed
10) Johkoh T, et al : Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol 84 : 542-546, 2015.
PubMed
11) Louza GF, et al : Lymphocytic interstitial pneumonia : computed tomography findings in 36 patients. Radiol Bras 53 : 287-292, 2020.
PubMed
12) Koss MN, et al : Lymphoid interstitial pneumonia : clinicopathological and immunopathological findings in 18 cases. Pathology 19 : 178-185, 1987.
 
13) Strimlan CV, et al : Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann Intern Med 88 : 616-621, 1978.
PubMed
14) Dufour V, et al : Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Clin Infect Dis 36 : e127-130, 2003.
PubMed
15) Innes AL, et al : Resolution of lymphocytic interstitial pneumonitis in an HIV infected adult after treatment with HAART. Sex Transm Infect 80 : 417-418, 2004.
 
16) Kourtis AP, et al : Trends in hospitalizations of HIV-infected children and adolescents in the United States : analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics 120 : e236-243, 2007.
PubMed
P.114 掲載の参考文献
1) Lofgren S : Erythema nodosum. Studies on etiology and pathogenesis in 185 adult cases. Acta Med Scand 124 (Suppl 174) : 1-197, 1946.
 
2) Lofgren S, Lundback H : The bilateral hilar lymphoma syndrome ; a study of the relation to age and sex in 212 cases. Acta Med Scand 142 : 259-264, 1952.
PubMed
3) Lofgren S, Lundback H : The bilateral hilar lymphoma syndrome ; a study of the relation to tuberculosis and sarcoidosis in 212 cases. Acta Med Scand 142 : 265-273, 1952.
PubMed
4) Grunewald J, Eklund A : Sex-specific manifestations of Lofgren's syndrome. Am J Respir Crit Care Med 175 : 40-44, 2007.
 
5) Selroos O : The frequency, clinical picture and prognosis of pulmonary sarcoidosis in Finland. Acta Med Scand Suppl 503 : 3-73, 1969.
PubMed
6) 日本サルコイドーシス/肉芽腫性疾患学会 : Lofgren症候群. [https://www.jssog.com/wp/wp-content/themes/jssog/images/system/guidance/2-6-1.pdf] (2021年8月閲覧)
 
7) Wilsher ML : Seasonal clustering of sarcoidosis presenting with erythema nodosum. Eur Respir J 12 : 1197-1199, 1998.
PubMed
8) 山口悦郎, 川上義和 : サルコイドーシスの成因論 遺伝的背景-HLAを中心に-. 日本臨牀 60 : 1679-1687, 2002.
 
9) Mana J, et al : Lofgren's syndrome revisited : a study of 186 patients. Am J Med 107 : 240-245, 1999.
 
10) Gran JT, Bohmer E : Acute sarcoid arthritis : a favourable outcome? A retrospective survey of 49 patients with review of the literature. Scand J Rheumatol 25 : 70-73, 1996.
PubMed
11) Hedfors E, Lindstrom F : HLA-B8/DR3 in sarcoidosis. Correlation to acute onset disease with arthritis. Tissue Antigens 22 : 200-203, 1983.
PubMed
P.118 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Pagnoux C, Guillevin L : Churg-Strauss syndrome : evidence for disease subtypes? Curr Opin Rheumatol 22 : 21-28, 2010.
PubMed
3) 難病情報センター : 平成30年度 衛生行政報告例 平成30年度末現在. [https://www.nanbyou.or.jp/wp-content/uploads/upload_files/koufu20191.pdf] (2021年9月閲覧)
 
4) Bonatti F, et al : Genetic Susceptibility to ANCA-Associated Vasculitis : State of the Art, Front Immunol 5 : 577, 2014.
PubMed
5) Hellmich B, et al : Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci 1051 : 121-131, 2005.
PubMed
6) Lepse N, et al : Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. Rheumatology (Oxford) 55 : 162-172, 2016.
PubMed
7) Wechsler ME, et al : Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. Engl J Med 376 : 1921-1932, 2017.
 
8) Tsurikisawa N, et al : Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. Clin Exp Allergy 48 : 1305-1316, 2018.
PubMed
9) Masi AT, et al : The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33 : 1094-1100, 1990.
PubMed
10) 日本循環器学会, ほか : 2015-2016年度活動 血管炎症候群の診療ガイドライン (2017年改訂版), 2018. [https://www.j-circ.or.jp/old/guideline/pdf/JCS2017_isobe_h.pdf] (2021年9月閲覧)
 
11) 抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究 : 針谷正祥編), 診断と治療社, 2021.
 
12) Moosig F, et al : A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA) : monocentric experiences in 150 patients. Ann Rheum Dis 72 : 1011-1017, 2013.
PubMed
13) Guillevin L, et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
P.121 掲載の参考文献
1) Sawahata M, Sugiyama Y : An epidemiological perspective of the pathology and etiology of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 33 : 112-116, 2016.
PubMed
2) サルコイドーシス診療の手引き 2018 (日本サルコイドーシス/肉芽腫性疾患学会サルコイドーシス診療の手引き作成委員会編), 2018. [https://www.jssog.com/journal#journal-guide] (2021年8月閲覧)
 
3) Yamaguchi T, et al : Immunohistochemical Detection of Potential Microbial Antigens in Granulomas in the Diagnosis of Sarcoidosis. J Clin Med 10 : 983, 2021.
PubMed
4) Negi M, et al : Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol 25 : 1284-1297, 2012.
PubMed
5) 山口哲生, 江石義信 : アクネ菌病因論で考えるサルコイドーシス学. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 39 : 1-10, 2019.
Medical*Online
6) Ishige I, et al : Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22 : 33-42, 2005.
PubMed
7) Alexeyev OA, et al : Why we continue to use the name Propionibacterium acnes. Br J Dermatol 179 : 1227, 2018.
PubMed
8) Sawahata M, et al : Computed Tomography Images of Fibrotic Pulmonary Sarcoidosis Leading to Chronic Respiratory Failure. J Clin Med 9 : 142, 2020.
PubMed
P.126 掲載の参考文献
1) Cheung OY, et al : Surgical pathology of granulomatous interstitial pneumonia. Ann Diagn Pathol 7 : 127-138, 2003.
PubMed
2) Ohshimo S, et al : Differential diagnosis of granulomatous lung disease : clues and pitfalls : Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmuller and Alberto Cavazza. Eur Respir Rev 26 : 170012, 2017.
 
3) 北田清悟 : 肺非結核性抗酸菌症の診断と治療. 日本呼吸ケア・リハビリテーション学会誌 29 : 234-236, 2020.
 
4) Lacasse Y, et al : Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 168 : 952-958, 2003.
PubMed
5) Hanak V, et al : Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. Mayo Clin Proc 82 : 812-816, 2007.
PubMed
6) Ando M, et al : Japanese summer-type hypersensitivity pneumonitis. Geographic distribution, home environment, and clinical characteristics of 621 cases. Am Rev Respir Dis 144 : 765-769, 1991.
PubMed
7) Okamoto T, et al : Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51 : 191-199, 2013.
PubMed
8) Morell F, et al : Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis : a prospective case-cohort study. Lancet Respir Med 1 : 685-694, 2013.
 
9) Ohtani Y, et al : Chronic bird fancier's lung : histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 60 : 665-671, 2005.
PubMed
10) Tsutsui T, et al : Antigen avoidance tests for diagnosis of chronic hypersensitivity pneumonitis. Respir Investig 53 : 217-224, 2015.
PubMed
11) Gimenez A, et al : Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax 73 : 391-392, 2018.
PubMed
12) Baughman RP, et al : A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 183 : 573-581, 2011.
PubMed
13) Grunewald J, Eklund A : Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc 4 : 461-464, 2007.
PubMed
14) Kishi M, et al : Pathogenesis of cBFL in common with IPF? Correlation of IP-10/TARC ratio with histological patterns. Thorax 63 : 810-816, 2008.
PubMed
15) Inoue Y, et al : Acute inflammatory and immunologic responses against antigen in chronic bird-related hypersensitivity pneumonitis. Allergol Int 68 : 321-328, 2019.
PubMed
P.130 掲載の参考文献
1) 武村民子 : 病理像からみた肉芽腫性疾患の鑑別. 病理と臨床 24 : 60-67, 2006.
Medical*Online
2) Leduc D, et al : Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 104 : 1620-1623, 1993.
PubMed
3) Pagan AJ, Ramakrichnan L : The Formation and Function of Granulomas. Annu Rev Immunol 36 : 639-665, 2018.
 
4) 津田富康, 北真治 : サルコイドーシス肉芽腫病変の免疫組織化学的研究. 日本臨牀 52 : 1456-1461, 1994.
 
5) Black MM, Epstein WL : Formation of multinucleate giant cells in organized epitheloid cell granulomas. Am J Pathol 74 : 263-274, 1974.
PubMed
6) Rosen Y : Pathology of sarcoidosis. Semin Respir Crit Care Med 28 : 36-52, 2007.
PubMed
7) Tanaka A, et al : Epithelioid granuloma formation requiring no T-cell function. Am J Pathol 106 : 165-170, 1982.
 
8) Jagadha V, et al : Granulomatous inflammation in the acquired immune deficiency syndrome. Am J Clin Pathol 84 : 598-602, 1985.
PubMed
9) 北市正則 : サルコイドーシス以外の肉芽腫性疾患 病理. サルコイドーシスとその他の肉芽腫性疾患 (安藤正幸, 四元秀毅監, 日本サルコイドーシス/肉芽腫性疾患学会編), p249-256, 克誠堂出版, 2006.
 
10) Williams WJ, Kelland D : New aid for diagnosing chronic beryllium disease (CBD) : laser ion mass analysis (LIMA). J Clin Pathol 39 : 900-901, 1986.
 
11) 宮崎泰成 : 過敏性肺炎 診断と治療のアップデート. アレルギー 69 : 329-333, 2020.
Medical*Online
12) 宮崎泰成, ほか : サルコイドーシスとその周辺疾患-肺肉芽腫性疾患-. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 36 : 27-30, 2016.
Medical*Online
13) 江石義信 : サルコイドーシスの病因をめぐって. 病理と臨床 24 : 18-27, 2006.
Medical*Online
14) Costabel U, et al : Hypersensitivity pneumonitis. Nat Rev Dis Primers 6 : 65, 2020.
PubMed
15) 呼吸器科医のためのサルコイドーシス診療ガイド (杉山幸比古監, 山口哲生, 四十坊典晴編), p170-192, 南江堂, 2016.
 
P.135 掲載の参考文献
1) van Slegtenhorst M, et al : Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277 : 805-808, 1997.
PubMed
2) The European Chromosome 16 Tuberous Sclerosis Consortium : Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75 : 1305-1315, 1993.
PubMed
3) 金田眞理, ほか : 結節性硬化症の診断基準及び治療ガイドライン-改訂版-. 日本皮膚科学会雑誌 128 : 1-16, 2018.
 
4) O'Callaghan FJK, et al : Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet 351 : 1490, 1998.
 
5) El-Hashemite N, et al : Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361 : 1348-1349, 2003.
PubMed
6) McCormack FX : Lymphangioleiomyomatosis-a clinical update. Chest 133 : 507-516, 2008.
PubMed
7) Tuberous Sclerosis Complex : Genes, Clinical Features and Therapeutics (ed by Kwiatkowski DJ, et al), Wiley-Blackwell, Weinheim, 2010.
 
8) Fraser RS, et al : フレイザー 呼吸器病学エッセンス (清水英治, 藤田次郎監訳), p504-508, 西村書店, 2009.
 
9) Popper HH : Micronodular hyperplasia of type II pneumocytes. Histopathology 20 : 281, 1992.
PubMed
10) Liebow AA, et al : Benign clear cell ("sugar") tumors of the lung. Yale J Biol Med 43 : 213-222, 1971.
PubMed
11) Sen S, et al : PEComa (clear cell "sugar" tumor) of the lung : a benign tumor that presented with thrombocytosis. Ann Thorac Surg 88 : 2013-2015, 2009.
 
12) Gaffey MJ, et al : Clear cell tumor of the lung. Immunohistochemical and ultrastructural evidence of melanogenesis. Am J Surg Pathol 15 : 644-653, 1991.
PubMed
P.140 掲載の参考文献
1) Rosen SH, et al : Pulmonary alveolar proteinosis. N Engl J Med 258 : 1123-1142, 1958.
PubMed
2) Inoue Y, et al : Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 177 : 752-762, 2008.
PubMed
3) Kitamura N, et al : Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution. ERJ Open Res 5 : 00190-2018, 2019.
PubMed
4) Akira M, et al : Pulmonary Fibrosis on High-Resolution CT of Patients With Pulmonary Alveolar Proteinosis. AJR Am J Roentgenol 207 : 544-551, 2016.
PubMed
5) Uchida K, et al : GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 356 : 567-579, 2007.
PubMed
6) 肺胞蛋白症の診断, 治療, 管理の指針. 厚生労働省難治性疾患克服研究事業「肺胞蛋白症の難治化要因の解明と診断, 治療, 管理の標準化と指針の確立」に関する研究班 (研究代表者 : 井上義一), 平成23年度総合研究報告書, 2012.
 
7) Ramirez J, et al : Pulmonary Alveolar Proteinosis : A New Technique and Rationale for Treatment. Arch Intern Med 112 : 419-431, 1963.
PubMed
8) Seymour JF, Presneill JJ : Pulmonary alveolar proteinosis : progress in the first 44 years. Am J Respir Crit Care Med 166 : 215-235, 2002.
PubMed
9) Campo I, et al : Whole lung lavage therapy for pulmonary alveolar proteinosis : a global survey of current practices and procedures. Orphanet J Rare Dis 11 : 115, 2016.
PubMed
10) 杉本親寿, ほか : 全肺洗浄を施行した自己免疫性肺胞蛋白症8例の手技, 効果, 安全性の多面的評価. 日本呼吸器学会雑誌 49 : 569-576, 2011.
Medical*Online
11) Tazawa R, et al : Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med 381 : 923-932, 2019.
PubMed
12) Trapnell BC, et al : Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med 383 : 1635-1644, 2020.
PubMed
P.144 掲載の参考文献
1) Dranoff G, et al : Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264 : 713-716, 1994.
PubMed
2) Rosen SH, et al : Pulmonary alveolar proteinosis. N Engl J Med 258 : 1123-1142, 1958.
PubMed
3) Brasch F, et al : Surfactant proteins in pulmonary alveolar proteinosis in adults. Eur Respir J 24 : 426-435, 2004.
PubMed
4) Kitamura T, et al : Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190 : 875-880, 1999.
PubMed
5) Suzuki T, Trapnell BC : Pulmonary Alveolar Proteinosis Syndrome. Clin Chest Med 37 : 431-440, 2016.
PubMed
6) Inoue Y, et al : Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 177 : 752-762, 2008.
PubMed
7) Ishii H, et al : Clinical features of secondary pulmonary alveolar proteinosis : pre-mortem cases in Japan. Eur Respir J 37 : 465-468, 2011.
PubMed
8) Moriyama M, et al : Possible involvement of lung cells harboring an abnormal karyotype in the pathogenesis of pulmonary alveolar proteinosis associated with myelodysplastic syndrome. Ann Am Thorac Soc 12 : 1251-1253, 2015.
PubMed
9) 岡田慎理, ほか : 同種骨髄移植によって骨髄異形成症候群に伴う二次性肺胞蛋白症が軽快した1例. 日本内科学会雑誌 109 : 960-967, 2020.
 
10) Spinner MA, et al : GATA2 deficiency : a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 123 : 809-821, 2014.
PubMed
11) Ohmachi K, et al : Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase. Tokai J Exp Clin Med 33 : 146-149, 2008.
 
12) Yoshimura M, et al : ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. Int J Hematol 100 : 611-614, 2014.
PubMed
13) Costabel U, Nakata K : Pulmonary alveolar proteinosis associated with dust inhalation : not secondary but autoimmune? Am J Respir Crit Care Med 181 : 427-428, 2010.
 
14) Ishii H, et al : Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis : aretrospective cohort study in Japan. BMC Pulm Med 14 : 37, 2014.
 
15) Holbert JM, et al : CT features of pulmonary alveolar proteinosis. AJR Am J Roentgenol 176 : 1287-1294, 2001.
PubMed
16) Ishii H, et al : Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis. Chest 136 : 1348-1355, 2009.
PubMed
17) Cordonnier C, et al : Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 149 : 788-794, 1994.
PubMed
P.148 掲載の参考文献
1) 迎寛 : 肺胞出血 ; びまん性肺疾患. まれなびまん性肺疾患. 別冊日本臨牀新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p487-491, 日本臨牀社, 2008.
 
2) Lara AR, Schwarz MI : Diffuse alveolar hemorrhage. Chest 137 : 1164-1171, 2010.
PubMed
3) Park MS : Diffuse alveolar hemorrhage. Tuberc Respir Dis (Seoul) 74 : 151-162, 2013.
PubMed
4) 石田一雄, ほか : びまん性肺胞出血症候群の臨床的検討 (予後を中心として). 日本呼吸器学会雑誌 41 : 851-856, 2003.
Medical*Online
5) 角川智之, ほか : びまん性肺胞出血10例の検討. 気管支学 25 : 85-89, 2003.
Medical*Online
6) Travis WD, et al : A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 14 : 1112-1125, 1990.
PubMed
7) 有村義宏, ほか : ミエロペルオキシダーゼに対する抗好中球細胞質抗体陽性症例における肺病変の検討. リウマチ 35 : 46-55, 1995.
 
8) 大西尚, ほか : P-ANCA陽性びまん性肺胞出血症例の臨床的検討. 日本呼吸器学会雑誌 36 : 1017-1022, 1998.
Medical*Online
9) Lauque D, et al : Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM "O" P). Medicine (Baltimore) 79 : 222-233, 2000.
 
10) Zamora MR, et al : Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 76 : 192-202, 1997.
PubMed
11) Schwarz MI, et al : Diffuse alveolar hemorrhage and other rare infiltrate disorders. In : Murray & Nadel's Text book of Respiratory Medicine, 4th ed (ed by Mason RJ, et al), p1656-1678, Elsevier Saunders, Philadelphia, 2005.
 
12) Greco A, et al : Goodpasture's syndrome : a clinical update. Autoimmun Rev 14 : 246-253, 2015.
PubMed
13) 薬剤性肺障害の診断・治療の手引き [第2版] 2018 (日本呼吸器学会 薬剤性肺障害の診断・治療の手引き第2版作成委員会編), 日本呼吸器学会, 2018.
 
14) 中山雅之, ほか : プロピルチオウラシルが原因と考えられたMPO-ANCA関連肺胞出血の1例. 日本呼吸器学会雑誌 45 : 508-513, 2007.
Medical*Online
15) Davies DJ, et al : Segmental necrotising glomerulonephritis with antineutrophil antibody : possible arbovirus aetiology? Br Med J (Clin Res Ed) 285 (6342) : 606, 1982.
PubMed
16) Little MA, et al : Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106 : 2050-2058, 2005.
PubMed
P.153 掲載の参考文献
1) Mariotta S, et al : Pulmonary alveolar microlithiasis : report on 576 cases published in the literature. Sarcoidosis Vasc Diffuse Lung Dis 21 : 173-181, 2004.
PubMed
2) Ferreira Francisco FA, et al : Pulmonary alveolar microlithiasis. State-of-the-art review. Respir Med 107 : 1-9, 2013.
PubMed
3) Tachibana T, et al : Pulmonary alveolar microlithiasis : review and management. Curr Opin Pulm Med 15 : 486-490, 2009.
PubMed
4) Sumikawa H, et al : Pulmonary alveolar microlithiasis : CT and pathologic findings in 10 patients. Monaldi Arch Chest Dis 63 : 59-64, 2005.
PubMed
5) Castellana G, et al : Pulmonary alveolar microlithiasis : review of the 1022 cases reported worldwide. Eur Respir Rev 24 : 607-620, 2015.
PubMed
6) 難治性びまん性肺疾患診療の手引き (厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班難治性びまん性肺疾患診療の手引き作成委員会編), 南江堂, 2017.
 
7) Huqun, et al : Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med 175 : 263-268, 2007.
PubMed
8) Corut A, et al : Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 79 : 650-656, 2006.
PubMed
9) Bendstrup E, Jonsson ALM : Pulmonary alveolar microlithiasis : no longer in the stone age. ERJ Open Res 6 : 00289-2020, 2020.
PubMed
10) Ishihara Y, et al : A case of pulmonary alveolar microlithiasis with an intragenetic deletion in SLC34A2 detected by a genome-wide SNP study. Thorax 64 : 365-367, 2009.
PubMed
11) Izumi H, et al : A novel SLC34A2 mutation in a patient with pulmonary alveolar microlithiasis. Hum Genome Var 4 : 16047, 2017.
 
12) Saito A, et al : Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. Sci Transl Med 7 : 313ra181, 2015.
PubMed
13) Levi M, et al : Mechanisms of phosphate transport. Nat Rev Nephrol 15 : 482-500, 2019.
PubMed
14) Poelma DL, et al : A common pathway for the uptake of surfactant lipids by alveolar cells. Am J Respir Cell Mol Biol 30 : 751-758, 2004.
PubMed
P.159 掲載の参考文献
1) Vassallo R, et al : Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 342 : 1969-1978, 2000.
PubMed
2) 井上義一 : ランゲルハンス細胞組織球症の病態と臨床 : 総括. 日本サルイコイドーシス/肉芽腫性疾患学会雑誌 29 : 95-97, 2009.
 
3) 井上義一 : ランゲルハンス細胞組織球症. 新臨床内科学 [第10版] (矢崎義雄監), p197-199, 医学書院, 2020.
 
4) Kobayashi M, et al : Clinical features and outcomes of adult Langerhans cell histiocytosis : a single-center experience. Int J Hematol 112 : 185-192, 2020.
PubMed
5) Badalian-Very G, et al : Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116 : 1919-1923, 2010.
PubMed
6) Liu H, et al : MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight 5 : e132048, 2020.
PubMed
7) Girschikofsky M, et al : Management of adult patients with Langerhans cell histiocytosis : recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 8 : 72, 2013.
 
8) Arai T, et al : Incipient stage of pulmonary Langerhans-cell histiocytosis complicated with pulmonary tuberculosis was examined by high-resolution computed tomography. Respir Med 99 : 1188-1190, 2005.
PubMed
9) 高野峻一, ほか : ネオシーダーによって再燃した肺ランゲルハンス細胞組織球症の1例. 日本呼吸器学会誌 9 : 43-47, 2020.
Medical*Online
10) Morimoto A, et al : Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol 97 : 103-108, 2013.
 
11) Howarth DM, et al : Langerhans cell histiocytosis : diagnosis, natural history, management, and outcome. Cancer 85 : 2278-2290, 1999.
PubMed
12) Vassallo R, et al : Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 346 : 484-490, 2002.
PubMed
13) Wajda N, et al : Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis. Respirology 25 : 644-650, 2020.
PubMed
P.163 掲載の参考文献
1) Chan ED, et al : Calcium deposition with or without bone formation in the lung. Am J Respir Crit Care Med 165 : 1654-1669, 2002.
PubMed
2) Belem LC, et al : Metastatic pulmonary calcification : state-of-the-art review focused on imaging findings. Respir Med 108 : 668-676, 2014.
PubMed
3) Mulligan RM : Metastatic calcification. Arch Pathol (Chic) 43 : 177-230, 1947.
PubMed
4) Bell NH, et al : Hypercalcemia associated with increased circulating 1, 25 dihydroxyvitamin D in a patient with pulmonary tuberculosis. Calcif Tissue Int 37 : 588-591, 1985.
 
5) Conger JD, et al : Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies. Ann Intern Med 83 : 330-336, 1975.
PubMed
6) Neff M, et al : Extensive metastatic calcification of the lung in an azotemic patient. Am J Med 56 : 103-109, 1974.
 
7) Gruden JF, et al : Dendriform pulmonary ossification in the absence of usual interstitial pneumonia : CT features and possible association with recurrent acid aspiration. AJR Am J Roentgenol 209 : 1209-1215, 2017.
PubMed
8) Peros-Golubicic T, Tekavec-Trkanjec J : Diffuse pulmonary ossification : an unusual interstitial lung disease. Curr Opin Pulm Med 14 : 488-492, 2008.
PubMed
9) Bendayan D, et al : Pulmonary calcifications : a review. Respir Med 94 : 190-193, 2000.
PubMed
10) Greenberg S, Suster B : Metastatic pulmonary calcification : appearance on high resolution CT. J Comput Assist Tomogr 18 : 497-499, 1994.
PubMed
11) Hartman TE, et al : Metastatic pulmonary calcification in patients with hypercalcemia : findings on chest radiographs and CT scans. AJR Am J Roentgenol 162 : 799-802, 1994.
PubMed
12) Brodeur FJ Jr, Kazerooni EA : Metastatic pulmonary calcification mimicking air-space disease. Technetium-99m-MDP SPECT imaging. Chest 106 : 620-622, 1994.
PubMed
13) Thurley PD, et al : Case report : Rapidly progressive metastatic pulmonary calcification : evolution of changes on CT. Br J Radiol 82 : e155-159, 2009.
 
14) Fulladosa X, et al : Metastatic pulmonary calcifications in severe secondary hyperparathyroidism : evolution after renal transplantation. Transplant Proc 27 : 2272-2276, 1995.
PubMed
15) Abe J, et al : Dendriform pulmonary ossification : unusual cause of spontaneous pneumothorax. Thorax 69 : 97-98, 2014.
PubMed
P.169 掲載の参考文献
1) 林田美江, ほか : 肺リンパ脈管筋腫症に関する全国疫学調査-追跡調査および第2回目全国横断調査-. 厚生労働省難治性疾患呼吸不全に関する調査研究, 平成19年度総括・分担研究報告書, p37-41, 2008.
 
2) Hayashida M, et al : The epidemiology of lymphangioleiomyomatosis in Japan : a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 12 : 523-530, 2007,
PubMed
3) Carsillo T, et al : Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97 : 6085-6090, 2000.
PubMed
4) Sato T, et al : Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47 : 20-28, 2002.
PubMed
5) Verhoef S, et al : High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 64 : 1632-1637, 1999.
PubMed
6) Franz DN, Krueger DA : mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. Am J Med Genet C Semin Med Genet 178 : 365-373, 2018.
PubMed
7) McCormack FX, et al : Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. N Engl J Med 364 : 1595-1606, 2011.
PubMed
8) Bissler JJ, et al : Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358 : 140-151, 2008.
 
9) Gupta N, et al : Lymphangioleiomyomatosis Diagnosis and Management : High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med 196 : 1337-1348, 2017.
 
10) Kurihara M, et al : A Total Pleural Covering for Lymphangioleiomyomatosis Prevents Pneumothorax Recurrence. PLoS One 11 : e0163637, 2016.
PubMed
11) 「結節性硬化症の診断基準及び治療ガイドライン」改訂委員会 ; 金田眞理, ほか : 結節性硬化症の診断基準及び治療ガイドライン-改訂版-. 日本皮膚科学会雑誌 128 : 1-16, 2018.
 
12) Klawitter J, et al : Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 14 : 1055-1070, 2015.
 
P.173 掲載の参考文献
1) Caplan A : Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax 8 : 29-37, 1953.
PubMed
2) Gough J, et al : Pathological studies of modified pneumoconiosis in coal-miners with rheumatoid arthritis ; Caplan's syndrome. Thorax 10 : 9-18, 1955.
 
3) Tellesson WG : Rheumatoid pneumoconiosis (Caplan's syndrome) in an asbestos worker. Thorax 16 : 372-377, 1961.
 
4) Caplan A, et al : A broader concept of Caplan's syndrome related to rheumatoid factors. Thorax 17 : 205-212, 1962.
PubMed
5) Schreiber J, et al : Rheumatoid pneumoconiosis (Caplan's syndrome). Eur J Intern Med 21 : 168-172, 2010.
PubMed
6) Benedek TG : Rheumatoid pneumoconiosis. Documentation of onset and pathogenic considerations. Am J Med 55 : 515-524, 1973.
PubMed
7) Honma K, Vallyathan V : Rheumatoid Pneumoconiosis : A Comparative Study of Autopsy Cases between Japan and North America. Ann Occup Hyg 46 (Suppl 1) : 265-267, 2002.
 
8) Arakawa H, et al : Computed tomography findings of Caplan syndrome. J Comput Assist Tomogr 27 : 758-760, 2003.
PubMed
9) National Institute for Occupational Safety and Health (NIOSH) : Study Syllabus for Classification of Radiographs of Pneumoconioses : Pathology Overview Pathology Basis of Occupational Lung Disease-Coal Workers' Pneumoconiosis (page last reviewed : August 5, 2020) [https://www.cdc.gov/niosh/learning/b-reader/pathology/pneumoconiosis/2.html]
 
10) Davies D, et al : Rheumatoid pneumoconiosis. A clinical study. Am Rev Respir Dis 97 : 617-629, 1968.
PubMed
11) Cooper GS, et al : Occupational exposures and autoimmune diseases. Int Immunopharmacol 2 : 303-313, 2002.
PubMed
12) Stolt P, et al : Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann Rheum Dis 69 : 1072-1076, 2010.
PubMed
13) Rozenberg D, et al : What to do with all of these lung nodules? Can Respir J 21 : e52-54, 2014.
 
14) Davies D : Treatment of rapidly progressive rheumatoid pneumoconiosis. Br J Ind Med 30 : 396-401, 1973.
PubMed
15) Toussirot E, et al : Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-α-blocking agent : a case series. J Rheumatol 36 : 2421-2427, 2009.
 
P.176 掲載の参考文献
1) Honma K, et al : Proposed criteria for mixed-dust pneumoconiosis : definition, descriptions, and guidelines for pathologic diagnosis and clinical correlation. Hum Pathol 35 : 1515-1523, 2004.
PubMed
2) Nagelschmidt G : The relation between lung dust and lung pathology in pneumoconiosis. Br J Ind Med 17 : 247-259, 1960.
PubMed
3) Gibbs AR, Wagner JC : Diseases due to silica. In : Pathology of Occupational Lung Disease (ed by Churg A, Green FHY), p155-175, Igaku-Shoin, New York, 1988.
 
4) Morgan WKC : Bronchitis, airways' obstruction and occupation. In : Occupational Lung Disorders, 3rd ed (ed by Parkes WR), p238-252, Butterworth-Heinemann, Oxford, 1994.
 
5) Shida H, et al : Radiologic and pathologic characteristics of mixed dust pneumoconiosis. Radiographics 16 : 483-498, 1996.
PubMed
P.179 掲載の参考文献
1) Allison AC, Hart PD : Potentiation by silica of the growth of Mycobacterium tuberculosis in macrophage cultures. Br J Exp Pathol 49 : 465-476, 1968.
PubMed
2) Honma K, Vallyathan V : Rheumatoid pneumoconiosis : Acomparative study of autopsy cases between Japan and North America. Ann Occup Hyg 46 (Suppl 1) : 265-267, 2002.
 
3) Gabay C, Kahn MF : Les sclerodermies masculines : role de l'exposition professionelle. Schweiz Med Wochenschr 122 : 1746-1752, 1992.
 
4) Honma K, Chiyotani K : Diffuse interstitial fibrosis in nonasbestos pneumoconiosis-a pathological study. Respiration 60 : 120-126, 1993.
PubMed
5) Arakawa H, et al : Chronic interstitial pneumonia in silicosis and mix-dust pneumoconiosis : its prevalence and comparison of CT findings with idiopathic pulmonary fibrosis. Chest 131 : 1870-1876, 2007.
PubMed
6) IARC Monographs on the evaluation of carcinogenic risks to humans, Vol 68-Silica, some silicates, coal dust and para-aramid fibrils, IARC, Lyon, 1997.
 
P.183 掲載の参考文献
1) Shaver CG, et al : Lung changes associated with the manufacture of alumina abrasives. J Ind Hyg Toxicol 29 : 145-157, 1947.
PubMed
2) Goralewski G : Zur Symptomatology der Aluminium-Staublungs. Arc Gew Ger 10 : 384-408, 1940.
 
3) 瀬良好澄, ほか : Aluminosisの1剖検例について. 診療 9 : 74-79, 1956.
 
4) Ueda M, et al : A case of aluminium dust lung. Kobe J Med Sci 4 : 91-99, 1958.
 
5) 小西池穣一, ほか : アルミ (アルミナ) 肺7症例の臨床的考察. 日本胸部臨床 39 : 195-204, 1980.
 
6) 田中英樹, ほか : アルミナ肺の1症例. 呼吸 8 : 435-439, 1989.
Medical*Online
7) 山本智生, ほか : 肺結核を合併したアルミニウム肺の1例, 呼吸 10 : 590-593, 1991.
Medical*Online
8) 犬塚賀奈子, ほか : 両側気胸を繰り返す上葉優位の肺線維化病変を呈したアルミニウム加工業者の1例. 日本呼吸器学会雑誌 48 : 492-496, 2010.
Medical*Online
9) Dinman BD : Aluminum in the lung : the pyropowder conundrum. J Occup Med 29 : 869-876, 1987.
PubMed
10) 渡部誠一郎, 坂谷光則 : アルミニウム肺. 最新医学 47 : 1337-1341, 1992.
Medical*Online
11) Stacy BD, et al : Tissue changes in rats' lungs caused by hydroxides, oxides and phosphates of aluminium and iron. J Pathol Bacteriol 77 : 417-426, 1959.
PubMed
12) Gilks B, et al : Aluminum-induced pulmonary fibrosis : do fibers play a role? Am Rev Respir Dis 136 : 176-179, 1987.
PubMed
13) Exley C, et al : Aluminum in tobacco and cannabis and smoking-related disease. Am J Med 119 : 276. e9-11, 2006.
 
14) Akira M : Uncommon pneumoconioses : CT and pathologic findings, Radiology 197 : 403-409, 1995.
PubMed
15) Simonsson BG, et al : Acute and long-term airway hyperreactivity in aluminium-salt exposed workers with nocturnal asthma. Eur J Respir Dis 66 : 105-118, 1985.
PubMed
16) Desjardins A, et al : Aluminium potroom asthma confirmed by monitoring of forced expiratory volume in one second. Am J Respir Crit Care Med 150 : 1714-1717, 1994.
PubMed
17) Taiwo OA, et al : Incidence of asthma among aluminum workers. J Occup Environ Med 48 : 275-282, 2006.
PubMed
18) Hull MJ, et al : Aluminum welding fume-induced pneumoconiosis. Hum Pathol 33 : 819-825, 2002.
PubMed
19) Chen WJ, et al : Aluminum induced pulmonary granuiomatosis, Hum Pathol 9 : 705-711, 1978.
PubMed
20) Herbert A, et al : Desquamative interstitial pneumonia in an aluminum welder. Hum Pathol 13 : 694-699, 1982.
 
21) Miller RR, et al : Pulmonary alveolar proteinosis and aluminum dust exposure. Am Rev Respir Dis 130 : 312-315, 1984.
PubMed
22) 渡辺孝一, 小林正義 : 病理組織切片内における金属元素分布の測定-EPMA元素マッピングの新しい活用法-. 表面科学 22 : 332-336, 2001.
 
23) Chino H, et al : Pulmonary Aluminosis Diagnosed with In-air Microparticle Induced X-ray Emission Analysis of Particles. Intern Med 54 : 2035-2040, 2015.
PubMed
24) Tomioka H, et al : Elemental analysis of occupational granulomatous lung disease by electron probe microanalyzer with wavelength dispersive spectrometer : Two case reports. Respir Med Case Rep 18 : 66-72, 2016.
PubMed
P.188 掲載の参考文献
1) 藤井保: 花莚業者の "い" 草染土による塵肺. 日本医学放射線学会雑誌 30 : 266-286, 1970.
 
2) 岸本卓巳, ほか : 西日本におけるイ草染土じん肺の臨床的検討. 日本職業・災害医学会会誌 50 : 97-101, 2002.
Medical*Online
3) 岸本卓巳, ほか : 広島県福山地方におけるい草染土塵肺の検討 : 胸部CT画像を用いて. 日本職業・災害医学会会誌 48 : 128-132, 2000.
 
4) Fujimoto K, et al : Pneumoconiosis in rush mat workers exposed to clay dye "sendo" dust : clinical, radiologic, and histopathologic features in seven patients. Chest 125 : 737-743, 2004.
PubMed
5) 伊藤清隆, ほか : 熊本県八代地方における, い草染土じん肺の画像的検討. 臨床放射線 44 : 133-138, 1999.
 
6) 加藤勝也, ほか : い草染土塵肺のCT所見の検討. 臨床放射線 49 : 167-172, 2004.
 
7) 岸本卓巳, ほか : 大陰影をきたした, い草染土塵肺症例の検討. 臨床放射線 44 : 127-132, 1999.
 
8) Xiao GB, et al : Lung disorders of workers exposed to rush smear dust in China. Ind Health 44 : 556-563, 2006.
 
P.192 掲載の参考文献
1) Farioli A, et al : Temporal Patterns of Exposure to Asbestos and Risk of Asbestosis : An Analysis of a Cohort of Asbestos Textile Workers. J Occup Environ Med 60 : 536-541, 2018.
PubMed
2) Ndlovu N, et al : Asbestos-related diseases in mineworkers : aclinicopathological study. ERJ Open Res 3 : 00022-2017, 2017.
 
3) Kishimoto T, et al : Clinical, radiological, and pathological investigation of asbestosis. Int J Environ Res Public Health 8 : 899-912, 2011.
PubMed
4) 岸本卓巳 : アスベスト肺の診断. 日本内科学会雑誌 96 : 2032-2038, 2007.
 
5) Akira M, et al : High-resolution CT of asbestosis and idiopathic pulmonary fibrosis. AJR Am J Roentgenol 181 : 163-169, 2003.
PubMed
6) 審良正則 : アスベスト関連肺疾患の画像診断. 日本胸部臨床 65 : 414-424, 2006.
Medical*Online
7) Arakawa H, et al : Asbestosis and other pulmonary fibrosis in asbestos-exposed workers : high-resolution CT features with pathological correlations. Eur Radiol 26 : 1485-1492, 2016.
PubMed
8) 岸本卓巳 : 長期間人工呼吸により管理可能であった石綿肺の1例. 日本胸部疾患学会雑誌 32 : 1006-1010, 1994.
 
9) American Thoracic Society. Medical Section of the American Lung Association : The diagnosis of nonmalignant diseases related to asbestos. Am Rev Respir Dis 134 : 363-368, 1986.
PubMed
10) Asbestos, asbestosis, and cancer : the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 23 : 311-316, 1997.
PubMed
11) American Thoracic Society : Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 170 : 691-715, 2004.
PubMed
12) Roggli VL, et al : Pathology of asbestosis-An update of the diagnostic criteria : Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society. Arch Pathol Lab Med 134 : 462-480, 2010.
PubMed
13) Berry G : Mortality of workers certified by pneumoconiosis medical panels as having asbestosis. Br J Ind Med 38 : 130-137, 1981.
PubMed
14) 森永謙二, ほか : 石綿肺患者の予後に関する研究. 日本災害医学会会誌 38 : 647-652, 1990.
 
15) Walters GI, et al : Asbestosis is prevalent in a variety of construction industry trades. NPJ prim Care Respir Med 28 : 11, 2018.
 
P.196 掲載の参考文献
1) Tanaka A, et al : Pulmonary Toxicity of Indium-Tin Oxide and Indium Phosphide after Intratracheal Instillations into the Lung of Hamsters. J Occup Health 44 : 99-102, 2002.
 
2) Homma T, et al : Interstitial pneumonia developed in a worker dealing with particles containing indium-tin oxide. J Occup Health 45 : 137-139, 2003.
 
3) Homma S, et al : Pulmonary fibrosis in an individual occupationally exposed to inhaled indiumtin oxide. Eur Respir J 25 : 200-204, 2005.
 
4) Chonan T, et al : Interstitial pulmonary disorders in indium-processing workers. Eur Respir J 29 : 317-324, 2007.
PubMed
5) 長南達也 : インジウム肺-発見から管理まで. 東北医学雑誌 126 : 173-176, 2014.
 
6) 野上裕子, ほか : インジウム吸入による肺障害について. 日本呼吸器学会雑誌 46 : 60-64, 2008.
Medical*Online
7) Amata A, et al : High levels of indium exposure relate to progressive emphysematous changes : a 9-year longitudinal surveiliance of indium workers. Thorax 70 : 1040-1046, 2015.
 
8) Cummings KJ, et al : Indium lung disease. Chest 141 : 1512-1521, 2012.
PubMed
9) Nagano K, et al : Inhalation carcinogenicity and chronic toxicity of indium-tin oxide in rats and mice. J Occup Health 53 : 175-187, 2011.
PubMed
10) National Toxicology Program : Toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-80-7) in F344/N rats and B6C3F1 mice (inhalation studies), NIH Publication No. 01-4433, U. S. Department of Health and Human Service, Public Health Service, National Institute of Health, Bethesda, 2001.
 
P.201 掲載の参考文献
1) Suga M, et al : Mechanisms accounting for granulomatous responses in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 14 : 131-138, 1997.
PubMed
2) Rylander R, et al : Humidifier fever and endotoxin exposure. Clin Allergy 8 : 511-516, 1978.
PubMed
3) Muittari A, et al : An epidemic of bath water fever-endotoxin alveolitis? Eur J Respir Dis Suppl 123 : 108-116, 1982.
PubMed
4) Banaszak EF, et al : Hypersensitivity pneumonitis due to contamination of an air conditioner. N Engl J Med 283 : 271-276, 1970.
PubMed
5) 阿部澄子, ほか : 過敏性肺臓炎Thermoactinomyces vulgarisによる1例. 日本胸部疾患学会雑誌 16 : 363, 1978.
 
6) 辻野一三, ほか : 加湿器による過敏性肺臓炎 (加湿器肺) の1例. 日本胸部疾患学会雑誌 30 : 1864-1868, 1992.
 
7) Ando M, et al : Difference in the phenotypes of bronchoalveolar lavage lymphocytes in patients with summer-type hypersensitivity pneumonitis, farmer's lung, ventilation pneumonitis, and bird fancier's lung : report of a nationwide epidemiologic study in Japan. J Allergy Clin Immunol 87 : 1002-1009, 1991.
PubMed
8) Okamoto T, et al : Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51 : 191-199, 2013.
PubMed
9) 樫田祐一, ほか : 鹿児島県で発症した農夫肺の2同胞例. 日本胸部疾患学会雑誌 30 : 1835-1841, 1992.
 
10) Thorn J : The inflammatory response in humans after inhalation of bacterial endotoxin : a review. Inflamm Res 50 : 254-261, 2001.
PubMed
11) Morrison DC, Kline LF : Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 118 : 362-368, 1977.
PubMed
12) Michel O : Systemic and local airways inflammatory response to endotoxin. Toxicology 152 : 25-30, 2000.
PubMed
13) 稲瀬直彦 : 過敏性肺炎の診断と治療. 日本内科学会雑誌 103 : 2269-2274, 2014.
 
14) 原田智也, ほか : 同室者の羽毛布団により再発した急性鳥関連過敏性肺炎の1例. 日本呼吸器学会雑誌 48 : 328-332, 2010.
Medical*Online
15) Ohnishi H, et al : Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis. BMC Pulm Med 14 : 129, 2014.
PubMed
16) 小椋正道, ほか : 患者宅環境の検索により原因を究明し得た加湿器肺の事例. 環境感染 20 : 99-104, 2005.
 
17) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
P.204 掲載の参考文献
1) 奥谷博俊 : 炭素系粉じんによる肺疾患. 胸部疾患 6 : 170-176, 1962.
 
2) 濱田薫, ほか : グラファイト肺症 : びまん性肺疾患. じん肺および室内・大気環境汚染による肺疾患. 別冊日本臨牀新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p550-552, 日本臨牀社, 2008.
 
3) Hanoa R : Graphite pneumoconiosis. A review of etiologic and epidemiologic aspects. Scand J Work Environ Health 9 : 303-314, 1983.
PubMed
4) Zenz C : Occupational pulmonary disease. In : Occupational Medicine-Principles and Practical Applications, 2nd ed, p213, Year Book Medical Publishers, Chicago, 1987.
 
5) Koopmann H : Beitrag zur frage der pneumokoniosen. Virchows Arch A : Pathol Anat 253 : 423-431, 1924.
 
6) Uragoda CG : Graphite pneumoconiosis and its declining prevalence in Sri Lanka. J Trop Med Hyg 92 : 422-424, 1989.
PubMed
7) Uragoda CG : A cohort study of graphite workers in Sri Lanka. Occup Med (Lond) 47 : 269-272, 1997.
PubMed
8) Spencer H : Graphite lung. In : Pathology of the Lung, p457-458, Pergamon Press, Oxford, 1985.
 
9) Merlo DF, et al : A mortality cohort study among workers in a graphite electrode production plant in Italy. Occup Environ Med 61 : e9, 2004.
 
10) Okutani H, et al : Graphite pneumoconiosis in carbon electrode makers. Proceedings of the XIVth international congress of occupational health, Madrid, Spain, 1963. International congress series No 62. Excerpta Medica Foundation, Amsterdam, 1964.
 
11) 井上優, ほか : 黒鉛肺の一例. 日本胸部臨床 1 : 58-63, 1982.
 
12) 小泉俊次郎, ほか : びまん性微細穎粒状陰影と塊状陰影を呈した黒鉛肺. 日本胸部疾患学会雑誌 12 : 274-277, 1974.
 
13) 海老原勇 : じん肺の病理-各種じん肺における粉じん巣の発生病理を中心に. 労働科学 56 : 191-230, 1980.
 
14) 審良正則 : その他のまれなじん肺症. 日本胸部臨床 73 : 1442-1450, 2014.
Medical*Online
15) Akira M : Uncommon pneumoconioses : CT and pathologic findings. Radiology 197 : 403-409, 1995.
PubMed
16) 斉藤芳晃, ほか : 炭素系じん肺における肺機能障害. 日本胸部疾患学会雑誌 16 (Suppl) : 175, 1978.
 
17) 櫻田二友, ほか : じん肺 (黒鉛肺) に合併し肺癌との鑑別が困難であった肺結核腫の1例. 日本胸部疾患学会雑誌 33 : 332-335, 1995,
 
18) 北田裕陸, ほか : 黒鉛肺に合併した肺癌の一剖検例. 肺癌 26 : 455, 1986.
 
P.208 掲載の参考文献
1) 産業医学振興財団 : 産業保健ハンドブック IV じん肺-臨床・予防管理・補償のすべて-, 産業医学振興財団, 2007.
 
2) 濱田薫, 木村弘 : 珪肺症 : びまん性肺疾患. じん肺および室内・大気環境汚染による肺疾患. 別冊日本臨牀新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p553-555, 日本臨牀社, 2008.
 
3) 土屋公威, 稲瀬直彦 : 慢性過敏性肺炎・粉塵曝露肺. Medical Practice 34 : 605-611, 2017.
Medical*Online
4) 城戸貴志, 迎寛 : 職業性粉じん曝露と職業性呼吸器疾患 (じん肺). 呼吸器内科 25 : 514-521, 2014.
 
5) 岸本卓巳 : 日本のじん肺の現状について. 日本職業・災害医学会会誌 53 : 54-60, 2005.
Medical*Online
6) Rose C : Silicosis. In : UpToDate. Post TW (ed), UpToDate, Waltham, MA. [https://www.uptodate.com] (2021年9月閲覧)
 
7) 相澤好治 : データで読む産業保健 (第8回) じん肺有所見者の推移. 産業保健 21 (93) : 28, 2018.
 
8) 荒川浩明 : 珪肺症とその合併症. 日本胸部臨床 73 : 1408-1415, 2014.
Medical*Online
9) Rimal B, et al : Basic pathogenetic mechanisms in silicosis : current understanding. Curr Opin Pulm Med 11 : 169-173, 2005.
PubMed
10) 土屋公威, 稲瀬直彦 : じん肺症 珪肺症. EBMを活かす呼吸器診療 (高橋和久, 児玉裕三編), p354-359, メジカルビュー社, 2015.
 
11) Choi EK, et al : The clinical value of F-18 FDG PET/CT in differentiating malignant from benign lesions in pneumoconiosis patients. Eur Radiol 30 : 442-451, 2020.
PubMed
12) Brown JM, et al : Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin Exp Immunol 131 : 415-421, 2003.
PubMed
13) 佐藤恵子, ほか : Caplan症候群 ; びまん性肺疾患. じん肺および室内・大気環境汚染による肺疾患. 別冊日本臨牀新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p521-525, 日本臨牀社, 2008.
 
14) Caplan A : Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax 8 : 29-37, 1953.
PubMed
15) 独立行政法人労働者健康安全機構 : 労災疾病等医学研究普及サイト 職業性呼吸器疾患. じん肺の健康管理. [https://www.researchjohas.go.jp/jinpai/13.html] (2021年9月閲覧)
 
16) 倉原優 : ポケット呼吸器診療 2021, シーニュ, 2021.
 
17) Ng TP, et al : Predictors of mortality in silicosis. Respir Med 86 : 115-119, 1992.
PubMed
18) Infante-Rivard C, et al : Lung cancer mortality and silicosis in Qurbec, 1938-85. Lancet 2 : 1504-1507, 1989.
PubMed
P.213 掲載の参考文献
1) Costa R, et al : Man-made mineral fibers and the respiratory tract. Arch Bronconeumol 48 : 460-468, 2012.
PubMed
2) 矢寺和博, ほか : 人造鉱物繊維と肺疾患 ; びまん性肺疾患. じん肺および室内・大気環境汚染による肺疾患. 別冊日本臨牀新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p556-559, 日本臨牀社, 2008.
 
3) 岩田耕治 : 人造鉱物繊維の概要. ニチアス技術時報 (382) : 12-17, 2018.
 
4) 矢野栄二 : 人造鉱物繊維 (MMMF) による肺疾患 ; 化学物質, 環境大気汚染による肺疾患. 別冊日本臨牀領域別症候群シリーズ No. 3 呼吸器症候群 (上巻), p545-548, 日本臨牀社, 1994.
 
5) Determination of airborne fibre number concentrations-A recommended method, by phase-contrast optical microscopy (membrane filter method), World Health Organization, Geneva. 1997. [https://www.who.int/occupational_health/publications/en/oehairbornefibre1.pdf?%20ua=%201] (2021年8月閲覧)
 
6) 戸塚優子 : 人造鉱物繊維の国内外規制について. ニチアス技術時報 (374) : 8-12, 2016.
 
7) IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans Vol 43, Man-Made Mineral Fibres and Radon, IARC, Lyon, 1988. [https://publications.iarc.fr/Book-And-Report-Series/larc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Man-Made-Mineral-Fibres-And-Radon-1988] (2021年8月閲覧)
 
8) 森本泰夫, 津田徹 : 人造鉱物繊維による肺障害. THE LUNG perspectives 6 : 406-412, 1998.
Medical*Online
9) 厚生労働省化学物質のリスク評価検討会 : リスク評価書 No. 69 (詳細) リフラクトリーセラミックファイバー (Refractory ceramic fibers) (別名セラミック繊維, RCF), 2014年7月. [https://www.mhlw.go.jp/file/05-Shingikai-11201000-Roudoukijunkyoku-Soumuka/0000080494.pdf] (2021年8月閲覧)
 
10) United Nations Environment Programme, International Labour Organisation, World Health Organization : International Programme on Chemical Safety. Environmental Health Criteria 77, Man-made Mineral Fibres, World Health Organization, Geneva, 1988. [http://apps.who.int/iris/bitstream/handle/10665/37217/WHO_EHC_77.pdf?sequence=1&isAllowed=y] (2021年8月閲覧)
 
11) Synthetic Vitreous Fibers. Documentation of the Threshold Limit Values and Biological Exposure Indices, 7th ed, American Conference of Governmental Industrial Hygienists. Cincinnati, 2001.
 
12) Mast RW, et al : Animal carcinogenicity and human epidemiology studies on refractory ceramic fiber Proceedings of 8th International Conference on Occupational Diseases, p480-483, ILO, Geneva, 1992.
 
13) Lemasters G, et al : Radiographic Changes among Workers Manufacturing Refractory Ceramic Fibre and Products. Ann Occup Hyg 38 (Suppl 1) : 745-751, 1994.
 
14) 日本産業衛生学会 : 許容濃度等の勧告 (2020年度). 産業衛生学雑誌 62 : 198-230, 2020.
Medical*Online
15) World Health Organization : Agents Classified by the IARC Monographs, Volumes 1-129. [https://monographs.iarc.who.int/agents-classified-by-the-iarc/] (2021年8月閲覧)
 
P.217 掲載の参考文献
1) Thorel C : Talc lung ; a contribution to the pathological anatomy of pneumoconiosis. Beitr Pathol Anat Allgem Pathol 20 : 85-101, 1896.
 
2) Vallyathan NV, Craighead JE : Pulmonary pathology in workers exposed to nonasbestiform talc. Hum Pathol 12 : 28-35, 1981.
PubMed
3) Gamble JF, et al : An epidemiologic study of a group of talc workers. Am Rev Respir Dis 119 : 741-753, 1979.
PubMed
4) Feigin DS : Talc : Understanding its manifestations in the chest. AJR Am J Roentgenol 146 : 295-301, 1986.
PubMed
5) Arnett EN, et al : Intravenous injection of talc-containing drugs intended to oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 60 : 711-718, 1976.
PubMed
6) Wild P, et al : Effects of talc dust on respiratory health : results of a longitudinal survey of 378 French and Austrian talc workers. Occup Environ Med 65 : 261-267, 2008.
PubMed
7) Marchiori E, et al : Pulmonary talcosis : imaging findings. Lung 188 : 165-171, 2010.
PubMed
8) Griffith CC, et al : Intravascular talcosis due to intravenoua drug use is an underrecognized cause of pulmonary hypertension. Pulm Med 2012 : 617531, 2012.
PubMed
9) Kleinfeld M, et al : Effect of Tale Dust Inhalation on Lung Function. Arch Environ Health 10 : 431-437, 1965.
PubMed
10) Akira M, et al : Inhalational talc pneumoconiosis : radiographic and CT findings in 14 patients. AJR Am J Roentgenol 188 : 326-333, 2007.
PubMed
11) Wild P, et al : A cohort mortality and nested case-control study of French and Austrian talc workers. Occup Environ Med 59 : 98-105, 2002.
 
12) Coggiola M, et al : An update of a mortality study of talc miners and millers in Italy. Am J Ind Med 44 : 63-69, 2003.
PubMed
13) Chang CJ, et al : Occupational exposure to talc increases the risk of lung cancer : a meta-analysis of occupational Cohort studies. Can Respir J 2017 : 1270608, 2017.
PubMed
P.222 掲載の参考文献
1) Petsonk EL, et al : Coal mine dust lung disease. New lessons from old exposure. Am J Respir Crit Care Med 187 : 1178-1185, 2013.
 
2) Perret JL, et al : Coal mine dust lung disease in the modern era. Respirology 22 : 662-670, 2017.
PubMed
3) Almberg KS, et al : Progressive massive fibrosis resurgence identified in U. S. coal miners filing for black lung benefits, 1970-2016. Ann Am Thorac Soc 15 : 1420-1426, 2018.
PubMed
4) Ulker O, et al : Serum and BAL cytokine and antioxidant enzyme levels at different stages of pneumoconiosis in coal workers. Hum Exp Toxicol 27 : 871-877, 2008.
PubMed
5) Huang C, et al : Role of bioavailable iron in coal dust-induced activation of activator protein-1 and nuclear factor of activated T cells : difference between Pennsylvania and Utah coal dusts. Am J Respir Cell Mol Biol 27 : 568-574, 2002.
PubMed
6) Nadif R, et al : IL18 and ILI8R1 polymorphisms, lung CT and fibrosis : A longitudinal study in coal miners. Eur Respir J 28 : 1100-1105, 2006.
 
7) Yucesoy B, et al : Genetic susceptibility to progressive massive fibrosis in coal miners. Eur Respir J 31 : 1177-1182, 2008.
PubMed
8) Go LHT, Cohen RA : Coal mine dust lung disease. In : Occupational and Environmental Lung Disease (ed by Feary J, et al), p176-189, European Respiratory Society, Sheffield, UK, 2020.
 
9) Antao VC, et al : Rapidly progressive coal workers' pneumoconiosis in the United States : geographic clustering and other factors. Occup Environ Med 62 : 670-674, 2005.
PubMed
10) Attfield MD, Hodous TK : Does regression analysis of lung function data obtained from occupational epidemiologic studies lead to misleading inferences regarding the true effect of smoking? Am J Ind Med 27 : 281-291, 1995.
PubMed
11) Miller BG, MacCalman L : Cause-specific mortality in British coal workers and exposure to respirable dust and quartz. Occup Environ Med 67 : 270-276, 2010.
PubMed
12) McConnochie K, et al : Interstitial fibrosis in coal workers : experience in Wales and West Virginia. Ann Occup Hyg 32 (Suppl 1) : 553-560, 1988.
 
13) Vallyathan V, et al : Radiographic and pathologic correlation of coal workers' pneumoconiosis. Am J Respir Crit Care Med 154 : 741-748, 1996.
PubMed
14) Laney AS, Petsonk EL : Small pneumoconiotic opacities on U. S. coal worker surveillance chest radiographs are not predominantly in the upper lung zones. Am J Ind Med 55 : 793-798, 2012.
 
15) 五十嵐毅, ほか : じん肺症における呼吸困難と治療. 日本職業・災害医学会会誌 54 : 156-159, 2006.
Medical*Online
16) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
P.225 掲載の参考文献
1) 海老原勇 : 炭素系じん肺 ; 化学物質, 環境大気汚染による肺疾患. 別冊日本臨牀領域別症候群シリーズ No. 3 呼吸器症候群 (上巻), p563-565, 日本臨牀社, 1994.
 
2) 堀口高彦, 立川壮一 : 炭素系じん肺 ; びまん性肺疾患. じん肺および室内・大気環境汚染による肺疾患. 別冊日本臨牀新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p566-568, 日本臨牀社, 2008.
 
3) Torres PPTS, et al : Wood charcoal dust pneumoconiosis. Rev Port Pneumol (2006) 23 : 233-234, 2017.
PubMed
4) Gloyne SR, et al : Pneumoconiosis due to graphite dust. Thorax 4 : 31-38, 1949.
PubMed
5) Mazzucchelli L, et al : Nonasbestos ferruginous bodies in sputum from a patient with graphite pneumoconiosis : a case report. Acta Cytol 40 : 552-554, 1996.
PubMed
6) Dong J, Ma Q : Myofibroblasts and lung fibrosis induced by carbon nanotube exposure. Part Fibre Toxicol 13 : 60, 2016.
PubMed
P.229 掲載の参考文献
1) Bech AO, et al : Hard metal disease. Br J Ind Med 19 : 239-252, 1962.
 
2) Ohori NP, et al : Giant-cell interstitial pneumonia and hard-metal pneumoconiosis. A clinicopathoiogic study of four cases and review of the literature. Am J Surg Pathol 13 : 581-587, 1989.
PubMed
3) Jobs H, Ballhausen C : Metallkeramik als Staubquelle vom arztlichen und technischen Standpunkt. Vertrauensarzt und Krankenkasse 8 : 142-148, 1940.
 
4) 日下幸則, ほか : 超硬合金粉じんによる気管支肺疾患 : 医学的調査結果を中心にして. 産業医学 : 24 : 636-648, 1982.
 
5) Coates EO, Watson JHL : Diffuse interstitial lung disease in tungsten carbide workers. Ann Intern Med 75 : 709-716, 1971.
 
6) Liebow AA, Carrington CB : The interstitial pneumonias. In : Frontiers of Pulmonary Radiology (ed by Simon M, et al), p102-141, Grune and Stratton, New York, 1969.
 
7) Abraham JL : Lung pathology in 22 cases of Giant cell interstitial pneumonia (GIP) suggests GIP is pathognomonic of cobalt (hard metal) disease [abstract]. Chest 91 : 312, 1987.
 
8) Demedts M, et al : Cobalt lung in diamond polishers. Am Rev Respir Dis 130 : 130-135, 1984.
PubMed
9) Fischbein A, et al : Clinical findings among hard metal workers. Br J Ind Med 49 : 17-24, 1992.
PubMed
10) Sprince NL, et al : Respiratory disease in tungsten carbide production workers. Chest 86 : 549-557, 1984.
PubMed
11) Tanaka J, et al : An observational study of giant cell interstitial pneumonia and lung fibrosis in hard metal lung disease. BMJ Open 4 : e004407, 2014.
PubMed
12) Lison D, et al : Experimental research into the pathogenesis of cobalt/hard metal lung disease. Eur Respir J 9 : 1024-1028, 1996.
PubMed
13) Potolicchio I, et al : Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA-DP beta chain. Eur J Immunol 27 : 2741-2743, 1997.
PubMed
14) Moriyama H, et al : Two-dimensional analysis of elements and mononuclear cells in hard metal lung disease. Am J Respir Crit Care Med 176 : 70-77, 2007.
PubMed
15) Chiba Y, et al : Hard Metal Lung Disease with Favorable Response to Corticosteroid Treatment : A Case Report and Literature Review. Tohoku J Exp Med 247 : 51-58, 2019.
PubMed
P.236 掲載の参考文献
1) 呼吸器専門医テキスト (工藤翔二, ほか編), p542, 南江堂, 2007.
 
2) Rose JJ, et al : Carbon Monoxide Poisoning : Pathogenesis, Management, and Future Directions of Therapy. Am J Respir Crit Care Med 195 : 596-606, 2017.
PubMed
3) Hardy KR, et al : Pathophysiology and treatment of carbon monoxide poisoning. J Toxicol Clin Toxicol 32 : 613-629, 1994.
PubMed
4) 北原多喜 : 急性塩素ガス中毒-ステロイドの大量療法が奏効した1例を中心にして. 日本胸部疾患学会雑誌 17 : 166-172, 1979.
 
5) 鈴木真輔, ほか : 発症に塩素系洗浄剤の関与が疑われた声門上狭窄の一症例. 喉頭 19 : 21-24, 2007.
Medical*Online
6) Scharf SM, et al : Pulmonary mechanics in dogs given different doses of kerosene intratracheally. Am Rev Respir Dis 126 : 695-700, 1982.
PubMed
7) 日下幸則 : 金属肺 ; 化学物質, 環境大気汚染による肺疾患. 別冊日本臨牀領域別症候群シリーズ No. 3 呼吸器症候群 (上巻), p531-534, 日本臨牀社, 1994.
 
8) Tafuri J, et al : Organophosphate poisoning. Ann Emerg Med 16 : 193-202, 1987.
PubMed
9) Asari Y, et al : Changes in the hemodynamic state of patients with acute lethal organophosphate poisoning. Vet Hum Toxicol 46 : 5-9, 2004.
PubMed
10) Summerhill EM, et al : An Official American Thoracic Society Workshop Report : Chemical Inhalational Disasters. Biology of Lung Injury, Development of Novel Therapeutics, and Medical Preparedness. Ann Am Thorac Soc 14 : 1060-1072, 2017.
PubMed
11) 呼吸器疾患最新の治療 2021-2022 (門田淳一, ほか編), 南江堂, 2021.
 
12) Anas N, et al : Criteria for hospitalizing children who have ingested products containing hydrocarbons. JAMA 246 : 840-843, 1981.
PubMed
13) 財団法人日本防災協会 : 火災における燃焼生成物の毒性に関する調査研究報告書, 1987.
 
14) Hampson NB : U. S. Mortality Due to Carbon Monoxide Poisoning 1999-2014. Accidental and Intentional Deaths. Ann Am Thorac Soc 13 : 1768-1774, 2016.
PubMed
15) Tibbles PM, et al : Treatment of carbon monoxide poisoning : a critical review of human outcome studies comparing normobaric oxygen with hyperbaric oxygen. Ann Emerg Med 24 : 269-276, 1994.
PubMed
16) Hampson NB, et al : Selection criteria utilized for hyperbaric oxygen treatment of carbon monoxide poisoning. J Emerg Med 13 : 227-231, 1995.
PubMed
17) Huang CC, et al : Hyperbaric Oxygen Therapy Is Associated With Lower Short-and Long-Term Mortality in Patients With Carbon Monoxide Poisoning. Chest 152 : 943-953, 2017.
 
18) Thom SR, et al : Delayed neuropsychologic sequelae after carbon monoxide poisoning : prevention by treatment with hyperbaric oxygen. Ann Emerg Med 25 : 474-480, 1995.
PubMed
19) Choi IS : Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol 40 : 433-435, 1983.
PubMed
20) 公益財団法人日本中毒情報センター : 医師向け中毒情報 (オリジナルファイル) データベース. [https://www.j-poison-ic.jp/medical-2/db/] (2021年9月閲覧)
 
21) Makrygianni EA, et al : Respiratory complications following hydrocarbon aspiration in children. Pediatr Pulmonol 51 : 560-569, 2016.
PubMed
22) Verma A, et al : Focal neuropathy preceding chronic inflammatory demyelinating poIyradiculoneuropathy by several years. Acta Neurol Scand 81 : 516-521, 1990.
PubMed
23) Carder JR, et al : Myocardial infarction after toluene inhalation. Pediatr Emerg Care 13 : 117-119, 1997.
PubMed
24) 豊嶋幹生, ほか : ニッケル粉塵吸入による好酸球性肺炎の1例. 日本胸部疾患学会雑誌 32 : 480-484, 1994.
 
25) Homma S, et al : Pulmonary fibrosis in an individual occupationally exposed to inhaled indiumtin oxide. Eur Respir J 25 : 200-204, 2005.
 
26) Sidell FR : Soman and sarin : clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 7 : 1-17, 1974.
PubMed
27) Eyer P : The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 22 : 165-190, 2003.
PubMed
28) Balali M : Clinical and laboratory findings in Iranian fighters with chemical gas poisoning. Arch Belg (Suppl) : 254-259, 1984.
PubMed
P.241 掲載の参考文献
1) Bradberry SM, et al : Glyphosate poisoning. Toxicol Rev 23 : 159-167, 2004.
PubMed
2) Bradberry SM, et al : Mechanisms of toxicity, clinical features, and management of acute chlorophenoxy herbicide poisoning : a review. J Toxicol Clin Toxicol 38 : 111-122, 2000.
PubMed
3) Roberts DM, Buckley NA : Paraquat Poisoning. In : UpToDate, Waltham, 2020.
 
4) Gawarammana IB, Dawson AH : Peripheral burning sensation : anovel clinical marker of poor prognosis and higher plasma-paraquat concentrations in paraquat poisoning. Clin Toxicol (Phila) 48 : 347-349, 2010.
 
5) 発生状況からみた急性中毒初期対応のポイント 農薬・工業用品 (TICs) 編/化学剤編 (日本中毒情報センター編), へるす出版, 2020.
 
6) 野口裕司, 金子直之 : 自殺企図によるパラコート中毒3例の報告 : 行政介入への提言. 日本救急医学会関東地方会雑誌 40 : 234-237, 2019.
 
7) Proudfoot AT, et al : Paraquat poisoning : Significance of plasma-paraquat concentrations. Lancet 314 : 330-332, 1979,
 
8) Sawada Y, et al : Severity index of paraquat poisoning. Lancet 331 : 1333, 1988.
 
9) Shen P, et al : Dynamic assessment of lung inj ury by ultrasound in patients with acute paraquat poisoning. J Int Med Res 48 : 300060520920435, 2020.
 
10) Twinem G, et al : Respiratory distress, pneumonic changes on chest X-ray, hypoxaemia, oral candidiasis in a homosexual male : not always Pneumocystis carinii pneumonia. Eur J Emerg Med 13 : 175-176, 2006.
 
P.245 掲載の参考文献
1) Cummings KJ, et al : A reconsideration of acute Beryllium disease. Environ Health Perspect 117 : 1250-1256, 2009.
PubMed
2) Hardy HL, Tabershaw IR : Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol 28 : 197-211, 1946.
PubMed
3) Kreiss K, et al : Chronic beryllium disease-from the workplace to celluiar immunology, molecular immunogenetics, and back. Clin Immunol Immunopathol 71 : 123-129, 1994.
 
4) Van Dyke MV, et al : Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med 183 : 1680-1688, 2011.
PubMed
5) Weston A, et al : Immunogenetic factors in beryllium sensitization and chronic beryllium disease. Mutat Res 592 : 68-78, 2005.
PubMed
6) 島正吾, 吉田勉 : ベリリウム取扱業務の健康管理. 化学物質取扱業務の健康管理, p54-74, 産業医学振興財団, 1993.
 
7) Mayer AS, et al : Sarcoidosis and chronic beryllium disease : similarities and differences. Semin Respir Crit Care Med 35 : 316-329, 2014.
PubMed
8) Mroz MM, et al : Effect of inhaled corticosteroids on lung function in chronic beryllium disease. Respir Med 138S : S14-S19, 2018.
PubMed
9) Sood A : Current treatment of chronic beryllium disease. J Occup Environ Hyg 6 : 762-765, 2009.
PubMed
10) Sood A, et al : Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 126 : 2000-2007, 2004.
 
11) Balmes JR, et al : An official American Thoracic Society statement : diagnosis and management of beryllium sensitivity and chronic beryllium disease. Am J Respir Crit Care Med 190 : e34-59, 2014.
PubMed
12) Marchand-Adam S, et al : Short-and long-term response to corticosteroid therapy in chronic beryllium disease, Eur Respir J 32 : 687-693, 2008.
 
13) Handa T, et al : Long-term complications and prognosis of chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 26 : 24-31, 2009.
PubMed
P.249 掲載の参考文献
1) Han D, et al : Thin-section CT findings of arc-welders' pneumoconiosis. Korean J Radiol 1 : 79-83, 2000.
PubMed
2) 吉井千春ほか : 溶接工肺-溶接ヒュームによる肺障害-. エアロゾル研究 20 : 238-242, 2005.
 
3) Cosgrove MP : Pulmonary fibrosis and exposure to steel welding fume. Occup Med (Lond) 65 : 706-712, 2015.
PubMed
4) Marek K, Starzynski Z : Pneumoconioses in Poland. Int J Occup Med Environ Health 7 : 13-21, 1994.
PubMed
5) Antonini JM : Health effects of welding. Crit Rev Toxicol 33 : 61-103, 2003.
PubMed
6) McCormick LM, et al : Pulmonary fibrosis secondary to siderosis causing symptomatic respiratory disease : a case report. J Med Case Rep 2 : 257, 2008.
PubMed
7) Funahashi A, et al : Welders' pneumoconiosis : tissue elemental microanalysis by energy dispersive x ray analysis. Br J Ind Med 45 : 14-18, 1988.
PubMed
P.254 掲載の参考文献
1) Raju S, et al : Indoor air pollution and respiratory health. Clin Chest Med 41 : 825-843, 2020.
PubMed
2) Godish T : Indoor environmental quality, CRC press, New York, 2016.
 
3) Shiraiwa M, et al : Aerosol health effects from molecular to global scales. Environ Sci Technol 51 : 13545-13567, 2017.
PubMed
4) Tran VV, et al : Indoor air pollution, related human diseases, and recent trends in the control and improvement of indoor air quality. Int J Environ Res Public Health 17 : 2927, 2020.
PubMed
5) USEPA : Indoor particulate matter, 2020. [https://www.epa.gov/indoor-air-quality-iaq/indoor-particulate-matter] (2021年8月閲覧)
 
6) 中島泰知, 織田 肇 : 窒素酸化物の生体影響. 環境技術 2 : 92-100, 1973.
 
7) Salonen H, et al : Human exposure to ozone in school and office indoor environments. Environ Int 119 : 503-514, 2018.
PubMed
8) Sporn TA, Roggli VL : Asbestosis. In : Pathology of asbestos-associated diseases, 3rd ed (ed by Oury TD, et al), p53-80, Springer, Berlin, 2014.
 
9) Assad NA, et al : Chronic obstructive pulmonary disease secondary to household air pollution. Semin Respir Crit Care Med 36 : 408-421, 2015.
PubMed
10) Rivera RM, et al : Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. Int J Tuberc Lung Dis 12 : 972-977, 2008.
PubMed
11) Moschovis PP, Hibberd PL : Household air pollution-related lung disease : protecting the children. Thorax 74 : 1018-1019, 2019.
PubMed
12) Chan KH, et al : Solid fuel use and risks of respiratory diseases. A cohort study of 280,000 Chinese never-smokers. Am J Respir Crit Care Med 199 : 352-361, 2019.
PubMed
13) Kamataki T, et al : Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives : application of genetically engineered Salmonella expressing human CYP. Drug Metab Rev 34 : 667-676, 2002.
PubMed
14) Metintas M, et al : Malignant mesothelioma due to environmental exposure to erionite : follow-up of a Turkish emigrant cohort. Eur Respir J 13 : 523-526, 1999.
PubMed
15) 石綿健康被害救済制度における平成18～令和元年度被認定者に関するばく露状況調査報告書, p1-154, 独立行政法人環境再生保全機構, 2021. [https://www.erca.go.jp/asbestos/chousa/pdf/18-r01_bakuro.pdf] (2021年8月閲覧)
 
P.258 掲載の参考文献
1) Cohen AJ, et al : Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution : an analysis of data from the Global Burden of Diseases Study 2015. Lancet 389 : 1907-1918, 2017.
PubMed
2) Schraufnagel DE, et al : Air Pollution and Noncommunicable Diseases : A Review by the Forum of International Respiratory Societies'Environmental Committee, Part 2 : Air Pollution and Organ Systems. Chest 155 : 417-426, 2019.
PubMed
3) World Health Organization : Ambient air pollution : aglobal assessment of exposure and burden of disease, 2016. [https://apps.who.int/iris/handle/10665/250141]
 
4) Kampa M, Castanas E : Human health effects of air pollution. Environ Pollut 151 : 362-367, 2008.
PubMed
5) Zheng XY, et al : Association between Air Pollutants and Asthma Emergency Room Visits and Hospital Admissions in Time Series Studies : A Systematic Review and Meta-Analysis. PLoS One 10 : e0138146, 2015.
PubMed
6) Doiron D, et al : Air pollution, lung function and COPD : results from the population-based UK Biobank study, Eur Respir J 54 : 1802140, 2019.
PubMed
7) United States Environmental Protection Agency : Integrated Science Assessment (ISA) for Oxides of Nitrogen-Health Criteria (Final Report, Jan 2016)
 
8) Katanoda K, et al : An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. J Epidemiol 21 : 132-143, 2011.
PubMed
9) Yang L, et al : The Impact of PM2.5 on the Host Defense of Respiratory System. Front Cell Dev Biol 8 : 91, 2020.
PubMed
10) Wu X, et al : Air pollution and COVID-19 mortality in the United States : Strengths and limitations of an ecological regression analysis. Sci Adv 6 : eabd4049, 2020.
PubMed
11) 環境省 : 平成30年度 別添1 : 大気汚染物質 (有害大気汚染物質等を除く) に係る常時監視測定結果.
 

VII 各種疾患にみられる呼吸器病変

P.264 掲載の参考文献
1) Goodpasture EW : The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 158 : 863-870, 1919.
 
2) Stanton MC, Tange JD : Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). Australas Ann Med 7 : 132-144, 1958.
PubMed
3) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
4) 進行性腎障害に関する調査研究班急速進行性腎炎症候群分科会 : 急速進行性腎炎症候群の診療指針 第2版. 日本腎臓学会誌 53 : 509-555, 2011.
 
5) Appel GB, et al : Anti-glomerular basement membrane disease and Goodpasture's syndrome. In : Brenner and Rector's the Kidney, 10th ed (ed by Skorecki K, et al), p1124-1127, Elsevier, Philadelphia, 2016.
 
6) Pedchenko V, et al : Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363 : 343-354, 2010.
PubMed
7) Kitagawa W, et al : The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant 23 : 3126-3129, 2008.
PubMed
8) Shah MK, et al : Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J 95 : 1411-1418, 2002.
 
9) Lazor R, et al : Alveolar hemorrhage in anti-basement membrane antibody disease : a series of 28 cases. Medicine (Baltimore) 86 : 181-193, 2007.
PubMed
10) Nagashima T, et al : Anti-glomerular basement membrane antibody disease : a case report and a review of Japanese patients with and without alveolar hemorrhage. Clin Exp Nephrol 6 : 49-57, 2002.
 
11) Sinico RA, et al : Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome : a comparison of different assays. Nephrol Dial Transplant 21 : 397-401, 2006.
 
12) エビデンスに基づく急速進行性腎炎症候群 (RPGN) 診療ガイドライン 2020 (厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎障害に関する調査研究班編), 東京医学社, 2020.
 
13) Segelmark M, Hellmark T : Anti-glomerular basement membrane disease : an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant 34 : 1826-1832, 2019.
PubMed
14) Hirayama K, et al : Anti-glomerular basement membrane antibody disease in Japan : part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol 12 : 339-347, 2008.
PubMed
15) McAdoo SP, et al : Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92 : 693-702, 2017.
PubMed
16) Cui Z, et al : Anti-glomerular basement membrane disease : outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine (Baltimore) 90 : 303-311, 2011.
 
P.271 掲載の参考文献
1) シェーグレン症候群診療ガイドライン [2017年版] (厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究班編), 診断と治療社, 2017.
 
2) Sumida T, et al : The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjogren's syndrome : a critical review. J Autoimmun 51 : 44-50, 2014.
PubMed
3) Fujibayashi T, et al : Revised Japanese criteria for Sjogren's syndrome (1999) : availability and validity. Mod Rheumatol 14 : 425-434, 2004.
PubMed
4) Seror R, et al : Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75 : 382-389, 2016.
PubMed
P.276 掲載の参考文献
1) Bywaters EG : Still's disease in the adult. Ann Rheum Dis 30 : 121-133, 1971.
PubMed
2) 三村俊英 : 成人Still病の診断と治療. 日本内科学会雑誌 107 : 1892-1898, 2018.
 
3) Asanuma YF, et al : Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol 25 : 393-400, 2015.
PubMed
4) Fujita Y, et al : HLA-DQB1 DPB1 alleles in Japanese patients with adult-onset Still's disease. Mod Rheumatol 29 : 843-847, 2019.
PubMed
5) Asano T, et al : Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still's disease. Arthritis Res Ther 19 : 199, 2017.
 
6) Chen DY, et al : Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 31 : 2189-2198, 2004.
PubMed
7) Chen DY, et al : Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63 : 1300-1306, 2004.
PubMed
8) Lee SJ, et al : Natural killer T cell deficiency in active adult-onset Still's Disease : correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum 64 : 2868-2877, 2012.
PubMed
9) Shimojima Y, et al : Characteristics of Circulating Natural Killer Cells and Their Interferon-γ Production in Active Adult-onset Still Disease. J Rheumatol 46 : 1268-1276, 2019.
 
10) Feist E, et al : Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol 14 : 603-618, 2018.
PubMed
11) Gerfaud-Valentin M, et al : Parenchymal lung involvement in adult-onset Still disease : A STROBE-compliant case series and literature review. Medicine (Baltimore) 95 : e4258, 2016.
PubMed
12) Ruscitti P, et al : Parenchymal lung disease in adult onset Still's disease : an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Res Ther 22 : 151, 2020.
PubMed
13) Yamaguchi M, et al : Preliminary criteria for classification of adult Still's disease. J Rheumatol 19 : 424-430, 1992.
 
14) Takakuwa Y, et al : Adult-onset Still's disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse. Clin Exp Rheumatol 37 (Suppl 121) : 23-27, 2019.
 
15) Ruscitti P, et al : Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease : Analysis of Survival Rates and Predictive Factors in the Gruppo ltaliano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. J Rheumatol 45 : 864-872, 2018.
 
P.280 掲載の参考文献
1) Braun J, Sieper J : Ankylosing spondylitis. Lancet 369 : 1379-1390, 2007.
PubMed
2) Appelrouth D, Gottlieb NL : Pulmonary manifestations of ankylosing spondylitis. J Rheumatol 2 : 446-453, 1975.
PubMed
3) Rosenow E, et al : Pleuropulmonary manifestations of ankylosing spondylitis. Mayo Clin Proc 52 : 641-649. 1977.
PubMed
4) Fenlon HM, et al : Plain radiographs and thoracic high-resolution CT in patients with ankylosing spondylitis. AJR Am J Roentgenol 168 : 1067-1072, 1997.
PubMed
5) Turetschek K, et al : Early pulmonary involvement in ankylosing spondylitis : assessment with thin-section CT. Clin Radiol 55 : 632-636, 2000.
PubMed
6) Kiris A, et al : Lung findings on high resolution CT in early ankylosing spondylitis. Eur J Radiol 47 : 71-76, 2003.
PubMed
7) El Maghraoui A, et al : Thoracic high resolution computed tomography in patients with ankylosing spondylitis and without respiratory symptoms. Ann Rheum Dis 62 : 185-186, 2003.
PubMed
8) El Maghraoui A, et al : Lung findings on thoracic high-resolution computed tomography in atients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin Rheumatol 23 : 123-128, 2004.
 
9) Altin R, et al : Comparison of early and late pleuropulmonary findings of ankylosing spondylitis by high-resolution computed tomography and effects on patients' daily life. Clin Rheumatol 24 : 22-28, 2005.
PubMed
10) Ayhan-Ardic FF, et al : Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 25 : 213-218, 2006.
PubMed
11) Sampaio-Barros PD, et al : Pulmonary involvement in ankylosing spondylitis. Clin Rheumatol 26 : 225-230, 2007.
PubMed
12) El Maghraoui A : Pleuropulmonary involvement in ankylosing spondylitis. Joint Bone Spine 72 : 496-502, 2005.
PubMed
13) Quismorio FP Jr : Pulmonary involvement in ankylosing spondylitis. Curr Opin Pulm Med 12 : 342-345, 2006.
PubMed
14) Jessamine AG : Upper lung lobe fibrosis in ankylosing spondylitis. Can Med Assoc J 98 : 25-29, 1968.
PubMed
15) Wolson AH, Rohwedder JJ : Upper lobe fibrosis in ankylosing spondylitis. Am J Roentgenol Radium Ther Nucl Med 124 : 466-471, 1975.
PubMed
16) Kchir MM, et al : Bronchoalveolar lavage and transbronchial biopsy in spondyloarthropathies. J Rheumatol 19 : 913-916, 1992.
 
17) Lee CC, et al : Spontaneous pneumothorax associated with ankylosing spondylitis. Rheumatology (Oxford) 44 : 1538-1541, 2005.
PubMed
18) Erb N, et al : Obstructive sleep apnoea as a cause of fatigue in ankylosing spondylitis. Ann Rheum Dis 62 : 183-184, 2003.
PubMed
19) Rohatgi PK, Turrisi BC : Bronchocentric granulornatosis and ankylosing spondylitis. Thorax 39 : 317-318, 1984.
PubMed
20) Shen TC, et al : The risk of asthma in patients with ankylosing spondylitis : a population-based cohort study. PLoS One 10 : e0116608, 2015.
PubMed
P.287 掲載の参考文献
1) Sharp GC, et al : Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52 : 148-159, 1972.
 
2) Tanaka Y, et al : 2019 Diagnostic criteria for mixed connective tissue disease (MCTD) : From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol 31 : 29-33, 2021.
PubMed
3) Nimelstein SH, et al : Mixed connective tissue disease : a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 59 : 239-248, 1980.
PubMed
4) 粕川禮司, ほか : 混合性結合組織病全国二次調査 個人票からみた病型分類の試み. 厚生省特定疾患混合性結合組織病調査研究班, 昭和61年度研究報告書, p19-23, 1987.
 
5) 鳥飼勝隆, ほか : 肺高血圧症を合併した混合性結合組織病患者の予後の検討. 厚生省特定疾患皮膚・結合組織疾患調査研究班混合性結合組織病分科会, 平成10年度研究報告書, p20-23, 1999.
 
6) Saito Y, et al : Pulmonary involvement in mixed connective tissue disease : Comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr 26 : 349-357, 2002.
PubMed
7) Yamanaka Y, et al : Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis. Eur J Radiol 107 : 26-32, 2018.
PubMed
8) 結合組織病に伴う肺動脈性肺高血圧症 (CTD-PAH) に対する基本的な情報提供. 結合組織病に伴う肺動脈性肺高血圧症診療ガイドライン (日本肺高血圧, 肺循環学会編), p7-18, レタープレス, 2019.
 
P.294 掲載の参考文献
1) Amarnani R, et al : Lupus and the Lungs : The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus. Front Med (Lausanne) 7 : 610257, 2020.
PubMed
2) Di Bartolomeo S, et al : Respiratory Manifestations in Systemic Lupus Erythematosus. Pharmaceuticals (Basel) 14 : 276, 2021.
PubMed
3) Lopez Velazquez M, Highland KB : Pulmonary manifestations of systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 30 : 449-464, 2018.
PubMed
4) Hahn BH : Systemic lupus erythematosus. In : Harrison's Principles of Internal Medicine, 20th ed (ed by Jameson JL, et al), p2515-2526, McGraw-Hill Education, Columbus, 2018.
 
5) Tanaka Y : State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis 23 : 465-471, 2020.
PubMed
6) Maria NI, Davidson A : Protecting the kidney in systemic lupus erythematosus : from diagnosis to therapy. Nat Rev Rheumatol 16 : 255-267, 2020.
PubMed
7) Tanaka Y, et al : Bcell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. Clin Immunol 186 : 21-25, 2018.
 
8) Zhang M, et al : Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation of BTB and CNC Homolog 2 by the Methyltransferase EZH2. Arthritis Rheumatol 72 : 1143-1153, 2020.
PubMed
9) Aringer M, et al : 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71 : 1400-1412, 2019.
PubMed
10) van Vollenhoven RF, et al : Treat-to-target in systemic lupus erythematosus : recommendations from an international task force. Ann Rheum Dis 73 : 958-967, 2014.
PubMed
11) Fanouriakis A, et al : Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80 : 14-25, 2021.
PubMed
P.300 掲載の参考文献
1) Cottin V, Brown KK : Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 20 : 13, 2019.
PubMed
2) Khanna D, et al : Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography : implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 17 : 372, 2015.
PubMed
3) 全身性強皮症 診断基準・重症度分類・診療ガイドライン委員会 : 浅野善英, ほか : 全身性強皮症 診断基準・重症度分類・診療ガイドライン. 日本皮膚科学会雑誌 126 : 1831-1896, 2016.
 
4) van den Hoogen F, et al : 2013 classification criteria for systemic sclerosis : an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72 : 1747-1755, 2013.
PubMed
5) Goh NS, et al : Interstitial lung disease in systemic sclerosis : a simple staging system. Am J Respir Crit Care Med 177 : 1248-1254, 2008.
PubMed
6) Steen VD, et al : Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37 : 1283-1289, 1994.
PubMed
7) Kuwana M, et al : Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. J Rheumatol 43 : 1825-1831, 2016.
 
8) Tashkin DP, et al : Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 : 2655-2666, 2006.
PubMed
9) Tashkin DP, et al : Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 : 1026-1034, 2007.
PubMed
10) Tashkin DP, et al : Mycophenolate mofetil versus oral cyclophosphamide in sclerodermarelated interstitial lung disease (SLS II) : a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4 : 708-719, 2016.
 
11) Khanna D, et al : Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate) : a phase 2, randomised, controlled trial. Lancet 387 : 2630-2640, 2016.
PubMed
12) Distler O, et al : Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 380 : 2518-2528, 2019.
PubMed
13) Khanna D, et al : An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease : the LOTUSS Trial. J Rheumatol 43 : 1672-1679, 2016.
 
14) Vonk MC, et al : Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67 : 98-104, 2008.
PubMed
15) Miele CH, et al : Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. Ann Am Thorac Soc 13 : 793-802, 2016.
PubMed
P.306 掲載の参考文献
1) Nakashima R, et al : Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25 : 925-933, 2016.
PubMed
2) Hamaguchi Y, et al : Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies : heterogeneity within the syndrome. PLoS One 8 : e60442, 2013.
PubMed
3) Hamaguchi Y, et al : Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis : a multicenter cross-sectional study. Arch Dermatol 147 : 391-398, 2011.
PubMed
4) Sato S, et al : Initial predictors of poor survival in myositis-associated interstitial lung disease : a multicentre cohort of 497 patients. Rheumatology (Oxford) 57 : 1212-1221, 2018.
PubMed
5) 中嶋蘭, 三森経世 : 抗MDA5 (meianoma differentiation-associated gene 5) 抗体と皮膚筋炎・急速進行性間質性肺炎. 日本臨床免疫学会会誌 36 : 71-76, 2013.
 
6) Bohan A, Peter JB : Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 : 344-347, 1975.
PubMed
7) 多発性筋炎・皮膚筋炎治療ガイドライン (厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究班多発性筋炎・皮膚筋炎分科会編), 診断と治療社, 2015.
 
8) Lundberg IE, et al : 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol 69 : 2271-2282, 2017.
PubMed
9) Lundberg IE, et al : 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76 : 1955-1964, 2017.
PubMed
10) Sato S, et al : Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23 : 496-502, 2013.
PubMed
11) Gono T, et al : Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49 : 1713-1719, 2010.
PubMed
12) Takei R, et al : Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig 58 : 83-90, 2020.
PubMed
13) Waseda Y, et al : Antisynthetase syndrome : Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol 85 : 1421-1426, 2016.
PubMed
14) Tanizawa K, et al : HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105 : 1380-1387, 2011.
PubMed
15) Hozumi H, et al : Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease : A Propensity Score-matched Analysis. J Rheumatol 46 : 509-517, 2019.
PubMed
16) Sasano H, et al : Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy. BMC Pulm Med 16 : 168, 2016.
PubMed
17) 特発性間質性肺炎診断と治療の手引き [改訂第3版] (日本呼吸器学会 びまん性肺疾患診断・治療ガイドライン作成委員会編), 南江堂, 2016.
 
18) Gono T, et al : Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. Arthritis Rheumatol 73 : 677-686, 2021.
PubMed
19) Tsuji H, et al : Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol 72 : 488-498, 2020.
PubMed
20) Shirakashi M, et al : Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford) 59 : 3284-3292, 2020.
PubMed
21) Shoji T, et al : Living-donor lobar lung transplantation for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis : report of a case. Gen Thorac Cardiovasc Surg 61 : 32-34, 2013.
PubMed
P.311 掲載の参考文献
1) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
 
2) Wang D, et al : Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol 15 : 581-596, 2019.
PubMed
3) 薬剤性肺障害の診断・治療の手引き [第2版] 2018 (日本呼吸器学会薬剤性肺障害の診断・治療の手引き第2版作成委員会編), 日本呼吸器学会, 2018.
 
4) 膠原病に伴う間質性肺疾患 診断・治療指針 2020 (日本呼吸器学会・日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針作成委員会編), 日本呼吸器学会/日本リウマチ学会, 2020.
 
5) Listing J, et al : The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52 : 53-61, 2013.
PubMed
6) Lake F, Proudman S : Rheumatoid arthritis and lung disease : from mechanisms to a practical approach. Semin Respir Crit Care Med 35 : 222-238, 2014.
PubMed
7) Bluett J, et al : Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. Rheumatol Ther 4 : 309-332, 2017.
PubMed
8) Matsumoto T, et al : Association between chest computed tomography findings and respiratory adverse events in rheumatoid arthritis patients undergoing long-term biological therapy. Int J Rheum Dis 22 : 626-635, 2019.
PubMed
9) 炎症性疾患に対する生物学的製剤と呼吸器疾患, 診療の手引き [第2版] (日本呼吸器学会 炎症性疾患に対する生物学的製剤と呼吸器疾患, 診療の手引き第2版作成委員会編), 日本呼吸器学会, 2020.
 
10) Smitten AL, et al : A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10 : R45, 2008.
PubMed
11) Nakajima A, et al : Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39 : 360-367, 2010.
PubMed
12) Hozumi H, et al : Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease : a retrospective case control study. BMJ Open 3 : e003132, 2013.
PubMed
13) 関節リウマチ (RA) に対するTNF阻害薬使用の手引き (2020年2月1日改訂版) (日本リウマチ学会ガイドライン委員会RA治療薬ガイドライン小委員会編). [https://www.ryumachi-jp.com/publish/guide/guideline_tnf/] (2021年8月閲覧)
 
14) 関節リウマチ (RA) に対するIL-6阻害薬使用の手引き (2020年2月1日改訂版) (日本リウマチ学会ガイドライン委員会RA治療薬ガイドライン小委員会編). [https://www.ryumachi-jp.com/publish/guide/guideline_il-6/] (2021年8月閲覧)
 
15) 全例市販後調査のためのトファシチニブ適正使用ガイド (2020年2月1日改訂版) (日本リウマチ学会ガイドライン委員会RA治療薬ガイドライン小委員会編). [https://www.ryumachi-jp.com/publish/guide/guideline_tofacitinib/] (2021年8月閲覧)
 
P.317 掲載の参考文献
1) 岡崎和一, ほか : IgG4関連疾患包括診断基準 2011. 日本内科学会雑誌 101 : 795-804, 2012.
 
2) 松井祥子, ほか : IgG4関連呼吸器疾患の診断基準. 日本呼吸器学会誌 4 : 129-132, 2015.
Medical*Online
3) Uchida K, et al : Prevalence of IgG4-Related Disease in Japan Based on Nationwide Survey in 2009. Int J Rheumatol 2012 : 358371, 2012.
PubMed
4) Umehara H, et al : A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details. Mod Rheumatol 22 : 1-14, 2012.
PubMed
5) Yamada K, et al : New clues to the nature of immunoglobulin G4-related disease : aretrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 19 : 262, 2017.
 
6) Terao C, et al : IgG4-related disease in the Japanese population : a genome-wide association study. Lancet Rheumatol 1 : e14-e22, 2019.
 
7) Shiokawa M, et al : Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med 10 : eaaq0997, 2018.
PubMed
8) Perugino CA, Stone JH : IgG4-related disease : an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol 16 : 702-714, 2020.
PubMed
9) Akiyama M, et al : Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Res Ther 18 : 167, 2016.
PubMed
10) Yoshikawa T, et al : Cytokines produced by innate immune cells in IgG4-related disease. Mod Rheumatol 29 : 219-225, 2019.
PubMed
11) Wallace ZS, et al : The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol 72 : 7-19, 2020.
PubMed
12) 梅原久範ほか : 2020年改訂IgG4関連疾患包括診断基準-The 2020 revised Comprehensive Diagnostic (RCD) Criteria for IgG4-RD-. 日本内科学会雑誌 110 : 962-969, 2021.
 
13) Matsui S : IgG4-related respiratory disease. Mod Rheumatol 29 : 251-256, 2019.
PubMed
14) 岡崎和一, ほか : 自己免疫性膵炎診療ガイドライン 2020. 膵臓 35 : 465-550, 2020.
 
15) Khosroshahi A, et al : International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol 67 : 1688-1699, 2015.
PubMed
16) Shiokawa M, et al : Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol 108 : 610-617, 2013.
PubMed
P.322 掲載の参考文献
1) Rook A : William Heberden's cases of anaphylactoid purpura. Arch Dis Child 33 : 271, 1958.
 
2) Schonlein JL : Allgemeine und Specielle Pathologie und Therapie, Vol 2, 3rd ed, p48, Herisau, Wurzburg, 1837.
 
3) 3) Henoch EH : Uber eine eigentumliche Form von Purpura. Berl Klin Wochenschr 11 : 641-643, 1874.
 
4) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
5) Gardner-Medwin JM, et al : Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360 : 1197-1202, 2002.
PubMed
6) Calvo-Rio V, et al : Henoch-Schonlein purpura in northern Spain : clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore) 93 : 106-113, 2014.
PubMed
7) Pillebout E, et al : Henoch-Schonlein Purpura in adults : outcome and prognostic factors. J Am Soc Nephrol 13 : 1271-1278, 2002.
PubMed
8) Nadrous HF, et al : Pulmonary involvement in Henoch-Schonlein purpura. Mayo Clin Proc 79 : 1151-1157, 2004.
PubMed
9) Audemard-Verger A, et al : Characteristics and Management of IgA Vasculitis (Henoch-Schonlein) in Adults : Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis Rheumatol 69 : 1862-1870, 2017.
 
10) Rajagopala S, et al : Pulmonary hemorrhage in Henoch-Schonlein purpura : case report and systematic review of the english literature. Semin Arthritis Rheum 42 : 391-400, 2013.
PubMed
11) Heineke MH, et al : New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schonlein purpura). Autoimmun Rev 16 : 1246-1253, 2017.
PubMed
12) Ozen S, et al : EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II : Final classification criteria. Ann Rheum Dis 69 : 798-806, 2010.
PubMed
13) Mills JA, et al : The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 33 : 1114-1121, 1990.
PubMed
14) IgA血管炎 IgA vasculitis (IgAV). 血管炎・血管障害診療ガイドライン 2016年改訂版. 日本皮膚科学会雑誌 127 : 332-340, 2017.
 
15) Miyoshi S, et al : Pulmonary Hemorrhaging as a Fatal Complication of IgA Vasculitis. Intern Med 57 : 3141-3147, 2018.
PubMed
16) Mirouse A, et al : Severe diffuse alveolar hemorrhage related to autoimmune disease : a multicenter study. Crit Care 24 : 231, 2020.
PubMed
P.327 掲載の参考文献
1) Touraine JL, et al : Combined immunodeficiency disease associated with absence of cell-surface HLA-A and -B antigens. J Pediatr 93 : 47-51, 1978.
 
2) Touraine JL : The bare-lymphocyte syndrome : Report on the registry. Lancet 317 : 319-321, 1981.
 
3) 杉山幸比古 : 副鼻腔気管支症候群. 日本臨牀 57 : 2119-2122, 1999.
Medical*Online
4) Sugiyama Y, et al : Progressive sinobronchiectasis associated with the "bare lymphocyte syndrome" in an adult. Chest 89 : 398-401, 1986.
 
5) 杉山幸比古, ほか : HLA-A, B, C locus欠如等のリンパ球異常を伴ったsino-bronchiectasisの1例. 日本胸部疾患学会雑誌 22 : 413-418, 1984
 
6) 杉山幸比古, ほか : びまん性汎細気管支炎様の臨床像を呈したBare Lymphocyte Syndromeの1例. 日本胸部疾患学会雑誌 27 : 980-983, 1989.
 
7) Maeda H, et al : Defective expression of HLA class I antigens : a case of the bare lymphocyte without immunodeficiency. Immunogenetics 21 : 549-558, 1985.
PubMed
8) Imaizumi Y : A recent survey of consanguineous marriages in Japan. Clin Genet 30 : 230-233, 1986.
PubMed
9) de la Salle H, et al : Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 265 : 237-241, 1994.
PubMed
10) Furukawa H, et al : Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 103 : 755-758, 1999.
PubMed
11) 杉山幸比古 : Bare lymphocyte症候群. 呼吸器内科 31 : 60-64, 2017.
 
12) 工藤翔二 : オーバービュー : マクロライド療法の現状と将来. 呼吸器内科 38 : 1-8, 2020.
 
13) 杉山幸比古 : Good症候群とびまん性汎細気管支炎. 日本胸部臨床 66 : 130-136, 2007.
Medical*Online
P.331 掲載の参考文献
1) Taylor FB, et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001.
 
2) 朝倉英策 : 播種性血管内凝固症候群 (DIC). 臨床に直結する血栓止血学 (朝倉英策編), p286-299, 中外医学社, 2018.
 
3) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会誌 20 : 77-113, 2009.
 
4) DIC診断基準作成委員会 : 日本血栓止血学会DIC診断基準 2017年版. 日本血栓止血学会誌 28 : 369-391, 2017.
 
5) Iba T, et al : New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition : aretrospective analysis of a nationwide survey. BMJ Open 7 : e017046, 2017.
 
6) Bone RC, et al : Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 61 : 585-589, 1976.
PubMed
7) Camprubi-Rimblas M, et al : Anticoagulant therapy in acute respiratory distress syndrome. Ann Transl Med 6 : 36, 2018.
PubMed
8) Katzenstein AL, et al : Diffuse alveolar damage-the role of oxygen, shock, and related factors. A review. Am J Pathol 85 : 209-228, 1976.
PubMed
9) Fukuda Y, et al : The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 126 : 171-182, 1987.
PubMed
10) Bachofen M, Weibel ER : Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 3 : 35-56, 1982.
PubMed
11) Bastarache JA, et al : The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 62 : 608-616, 2007.
PubMed
12) Idell S, et al : Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 261 (4 Pt 1) : L240-248, 1991.
 
13) Prabhakaran P, et al : Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J physiol Lung Cell Mol Physiol 285 : L20-28, 2003.
PubMed
P.336 掲載の参考文献
1) 高久智生 : 真性多血症-早期の診断, 血栓症の予防が重要. Hospitalist 3 : 820-828, 2015.
 
2) 小松則夫 : 真性赤血球増加症 (真性多血症). 内科学 (矢崎義雄総編集), p1982-1985, 朝倉書店, 2017.
 
3) James C, et al : A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 : 1144-1148, 2005.
 
4) Scott LM, et al : JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 : 459-468, 2007.
PubMed
5) Hodes PJ, Griffith JQ : Chest roentgenograms in polycythemia vera and polycythemia secondary to pulmonary arteriosclerosis. Am J Roentgenol 46 : 52-58, 1941.
 
6) Greening AP, et al : Carbon monoxide diffusing capacity in polycythaemia rubra vera. Thorax 37 : 528-531, 1982.
PubMed
7) Nugara C, et al : Polycitemia vera and pulmonary embolism : case report. Recenti Prog Med 104 : 643-645, 2013.
PubMed
8) 沖本二郎, ほか : 自験肺塞栓症例の初診時の臨床的検討. 救急医学 14 : 609-612, 1990.
 
9) 大西康貴, ほか : 肺梗塞を伴う急性肺血栓塞栓症の臨床的特徴. 日本呼吸器学会誌 10 : 17-24, 2021.
Medical*Online
10) Quarles van Ufford HM, et al : F-18 FDG PET in a patient with polycythemia vera. Clin Nucl Med 33 : 780-781, 2008.
 
11) 矢木晋, ほか : 真性多血症に合併し, アルキル化剤により治癒した特発性間質性肺炎の1例. 日本胸部疾患学会雑誌 28 : 1366-1371, 1990.
 
12) Neil JF, et al : Polycythaemia vera and central sleep apnoea. Br Med J 280 : 19, 1980.
 
13) Tirotta D, Durante V : A case of pulmonary sarcoidosis preceding polycythemia vera with literature review. Rheumatol Int 32 : 1347-1352, 2012.
PubMed
14) Girard A, et al : Hydroxyurea-induced pneumonia. Rev Mal Respir 31 : 430-434, 2014.
PubMed
P.342 掲載の参考文献
1) 廣川誠, ほか ; 赤芽球癆診療の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ : 赤芽球癆診療の参照ガイド令和1年改訂版 [第6版] (厚生労働科学研究費補助金難治性疾患等政策研究事業特発性造血障害に関する調査研究班 : 研究代表者三谷絹子), 2020. [http://zoketsushogaihan.umin.jp/file/2020/03.pdf] (2021年8月閲覧)
 
2) Means RT Jr : Pure red cell aplasia. Blood 128 : 2504-2509, 2016.
PubMed
3) Handgretinger R, et al : Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 340 : 278-284, 1999.
PubMed
4) Masuda M, et al : Clonal T cells of pure red-cell aplasia. Am J Hematol 79 : 332-333, 2005.
PubMed
5) Ishida F, et al : STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci 105 : 342-346, 2014.
PubMed
6) Kawakami T, et al : Frequent STAT3 mutations in cd8+ T cells from patients with pure red cell aplasia. Blood Adv 2 : 2704-2712, 2018.
PubMed
7) 難病情報センター : 後天性赤芽球癆 (指定難病283). [https://www.nanbyou.or.jp/entry/4451] (2021年6月閲覧)
 
8) Hirokawa M, et al : Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy : a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol 169 : 879-886, 2015.
 
9) Zhao J, et al : A systematic review of paraneoplastic syndromes associated with thymoma : Treatment modalities, recurrence, and outcomes in resected cases. J Thorac Cardiovasc Surg 160 : 306-314. e14, 2020.
 
10) Moriyama S, et al : Pure red cell aplasia associated with thymoma : a report of a single-center experience. J Thorac Dis 10 : 5066-5072, 2018.
PubMed
11) Thompson CA, Steensma DP : Pure red cell aplasia associated with thymoma : clinical insights from a 50-year single-institution experience. Br J Haematol 135 : 405-407, 2006.
PubMed
12) Hirokawa M, et al : Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia : a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93 : 27-33, 2008.
 
13) Weksler B, Lu B : Alterations of the immune system in thymic malignancies. J Thorac Oncol 9 (9 Suppl 2) : S137-142, 2014.
 
14) Wadhera A, et al : Thymoma-associated multiorgan autoimmunity : a graft-versus-host-like disease. J Am Acad Dermatol 57 : 683-689, 2007.
 
15) Nitta H, et al : Expansion of CD8+/perforin+effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasia. Br J Haematol 150 : 712-715, 2010.
PubMed
P.348 掲載の参考文献
1) Ramos-Casals M, et al : The cryoglobulinaemias. Lancet 379 : 348-360, 2012.
PubMed
2) 山村昌弘 : クリオグロブリン血症, クリオフィブリノゲン血症. Expert膠原病・リウマチ [改訂第4版] (住田孝之編), p128-135, 診断と治療社, 2019.
 
3) Sansonno D, et al : Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 46 : 572-578, 2007.
PubMed
4) Ferri C, et al : Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 82 : 3701-3704, 1993.
PubMed
5) Trejo O, et al : Cryoglobulinemia : study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 80 : 252-262, 2001.
PubMed
6) Viegi G, et al : Lung function in essential mixed cryoglobulinemia : a short-term follow-up. Clin Rheumatol 8 : 331-338, 1989.
 
7) Bertorelli G, et al : Subclinical pulmonary involvement in essential mixed cryoglobulinemia assessed by bronchoalveolar lavage. Chest 100 : 1478-1479, 1991.
PubMed
8) Ramos-Casals M, et al : Life-threatening cryoglobulinemia : clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 36 : 189-196, 2006.
PubMed
9) Amital H, et al : Alveolar hemorrhage in cryoglobulinemia-an indicator of poor prognosis. Clin Exp Rheumatol 23 : 616-620, 2005.
PubMed
10) 岸誠司, 土井俊夫 : クリオグロブリン血症. 日本内科学会雑誌 100 : 1289-1295, 2011.
 
11) De Vita S, et al : Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 70 : 1183-1190, 2011.
PubMed
12) Quartuccio L, et al : Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford) 53 : 2209-2213, 2014.
PubMed
13) Dammacco F, Sansonno D : Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 369 : 1035-1045, 2013.
PubMed
14) Saadoun D, et al : Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis : VASCUVALDIC study. Ann Rheum Dis 75 : 1777-1782, 2016.
PubMed
15) Montero N, et al : Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev 5 : CD011403, 2018.
PubMed
P.352 掲載の参考文献
1) Swerdlow SH, et al : Lymphoplasmacytic lymphoma. In : WHO Classification of Tumours, revised 4th ed, Vol 2, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p232-235, IARC Press, Lyon, 2017.
 
2) Sekiguchi N : Waldenstrom macroglobulinemia : Japanese perception]. Rinsho Ketsueki 60 : 988-997, 2019.
PubMed
3) Cao X, et al : Waldenstrom macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8 : 74, 2015.
PubMed
4) Minnema MC, et al : Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica 102 : 43-51, 2017.
PubMed
5) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 : 826-833, 2012.
PubMed
6) Yang G, et al : A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 122 : 1222-1232, 2013.
 
7) Poulain S, et al : Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. Clin Cancer Res 22 : 1480-1488, 2016.
PubMed
8) Argyropoulos KV, et al : Clonal B cells in Waldenstrom's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia 30 : 1116-1125, 2016.
PubMed
9) Sekiguchi N, et al : Gene expression profile signature of aggressive Waldenstrom macroglobulinemia with chromosome 6q deletion. Biomed Res Int 2018 : 6728128, 2018.
PubMed
10) Poulain S, et al : TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clin Cancer Res 23 : 6325-6335, 2017.
PubMed
11) Banwait R, et al : Extramedullary Waldenstrom macroglobulinemia. Am J Hematol 90 : 100-104, 2015.
PubMed
12) Varettoni M, et al : Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein : A multicentric study of the Rete Ematologica Lombarda (REL) network. Am J Hematol 94 : 1193-1199, 2019.
PubMed
13) Gustine JN, et al : MYD88 mutations can be used to identify malignant pleural effusions in Waldenstrom macroglobulinaemia. Br J Haematol 180 : 578-581, 2018.
PubMed
14) Okamura K, et al : Interstitial pulmonary amyloidosis with Waldenstrom's macroglobulinemia. Intern Med 54 : 353-354, 2015.
PubMed
15) 関口直宏 : 原発性マクログロブリン血症. medicina 52 : 2110-2113, 2015.
 
16) Toyoda K, et al : Mucosa-associated lymphoid tissue lymphoma with t (11 ; 18) (q21 ; q21) translocation : long-term follow-up results. Ann Hematol 98 : 1675-1687, 2019.
 
17) Castillo JJ, et al : Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia : an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 169 : 81-89, 2015.
PubMed
18) Dalal NH, et al : Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, 2000-2016. Br J Haematol 189 : 1107-1118, 2020.
PubMed
19) リンパ形質細胞性リンパ腫/ワルデンシュトレームマクログロブリン血症 (LPL/WM). 造血器腫瘍診療ガイドライン2018年版補訂版 [2020年4月] (日本血液学会編), p208-214, 金原出版, 2020.
 
20) Morel P, et al : International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113 : 4163-4170, 2009.
PubMed
21) Sekiguchi N, et al : A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia. Cancer Sci 111 : 3327-3337, 2020.
PubMed
P.359 掲載の参考文献
1) Abed Rabbo M, et al : Sphingolipid lysosomal storage diseases : from bench to bedside. Lipids Health Dis 20 : 44, 2021.
PubMed
2) 湯浅光織, 重松陽介 : 脂肪酸代謝異常症. 小児科 61 : 1371-1377, 2020.
 
3) Tran C, et al : Pulmonary Involvement in Adult Patients with Inborn Errors of Metabolism. Respiration 94 : 2-13, 2017.
PubMed
4) Jezela-Stanek A, et al : Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy : A state-of-the art review. Clin Respir J 14 : 422-429, 2020.
PubMed
5) Wasserstein MP, et al : Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD) : safety and efficacy in adults treated for 30 months. J Inherit Metab Dis 41 : 829-838, 2018.
PubMed
6) Minai OA, et al : Pulmonary involvement in Niemann-Pick disease : case report and literature review. Respir Med 94 : 1241-1251, 2000.
PubMed
7) Staretz-Chacham O, et al : Pulmonary involvement in Niemann-Pick C type 1. Eur J Pediatr 177 : 1609-1615, 2018.
 
8) Lundy CT, et al : Acute respiratory distress syndrome in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies. J Inherit Metab Dis 26 : 537-541, 2003.
PubMed
9) Goetzman ES, et al : Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction. J Biol Chem 289 : 10668-10679, 2014.
PubMed
P.364 掲載の参考文献
1) 糖原病と糖新生異常症 : 肝型糖原病. 新生児マススクリーニング対象疾患等診療ガイドライン 2019 (日本先天代謝異常学会編), p286-295, 診断と治療社, 2019.
 
2) Kishnani PS, et al : Diagnosis and management of glycogen storage disease type I : a practice guideline of the American College of Medical Genetics and Genomics. Genet Med 16 : e1, 2014.
PubMed
3) Humbert M, et al : Pulmonary arterial hypertension and type-I glycogen-storage disease : the serotonin hypothesis. Eur Respir J 20 : 59-65, 2002.
PubMed
4) Ueno M, et al : Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. Circ J 73 : 1965-1968, 2009.
 
5) Pizzo CJ : Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension. Pediatrics 65 : 341-343, 1980.
PubMed
6) Kim YM, et al : Predominance of the c.648G > T G6PC gene mutation and late complications in Korean patients with glycogen storage disease type Ia. Orphanet J Rare Dis 15 : 45, 2020.
 
7) Kishnani PS, et al : Aretrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148 : 671-676, 2006.
 
8) Winkel LP, et al : The natural course of non-classic Pompe's disease ; a review of 225 published cases. J Neurol 252 : 875-884, 2005.
 
9) Fukuda T, et al : Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 59 : 700-708, 2006.
 
10) Tsuburaya RS, et al : Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology. Neuromuscul Disord 22 : 389-393, 2012.
PubMed
11) Prater SN, et al : The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14 : 800-810, 2012.
PubMed
12) Regnery C, et al : 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35 : 837-845, 2012.
PubMed
13) Montagnese F, et al : Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD). J Inherit Metab Dis 39 : 391-398, 2016.
PubMed
P.369 掲載の参考文献
1) ムコ多糖症UPDATE (折居忠夫総監修/井田博幸, ほか編), イーエヌメディックス, 2011.
 
2) Muhlebach MS, et al : Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev 12 : 133-138, 2011.
PubMed
3) Semenza GL, Pyeritz RE : Respiratory complications of mucopolysaccharide storage disorders. Medicine (Baltimore) 67 : 209-219, 1988.
PubMed
4) Wraith JE, et al : Mucopolysaccharidosis type II (Hunter syndrome) : aclinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167 : 267-277, 2008.
 
5) Gonuldas B, et al : Mucopolysaccharidosis : Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway. Int J Pediatr Otorhinolaryngol 78 : 944-949, 2014.
PubMed
6) Giugliani R, et al : Management guidelines for mucopolysaccharidosis VI. Pediatrics 120 : 405-418, 2007.
PubMed
7) Yeung AH, et al : Airway management in children with mucopolysaccharidoses. Arch Otolaryngol Head Neck Surg 135 : 73-79, 2009.
PubMed
8) Bianchi PM, et al : ENT and mucopolysaccharidoses. Ital J Pediatr 44 : 127, 2018.
PubMed
9) ムコ多糖症 (MPS) II型診療ガイドライン 2019 (日本先天代謝異常学会編), p5, p13, 診断と治療社, 2019.
 
10) Guffon N, et al : Bone marrow transplantation in children with Hunter syndrome : outcome after 7 to 17 years. J Pediatr 154 : 733-737, 2009.
PubMed
11) Walker R, et al : Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 36 : 211-219, 2013.
PubMed
12) Mesolella M, et al : Management of otolaryngological manifestations in mucopolysaccharidoses : our experience. Acta Otorhinolaryngol Ital 33 : 267-272, 2013.
PubMed

VIII その他

P.375 掲載の参考文献
1) 堀口正治, ほか : 腹横筋膜から起こる横隔膜の筋束 (横筋筋膜部). 臨床解剖研究会記録 (1) : 4-5, 2001.
Medical*Online
2) Kelly KA, Bassett D : An Anatomic Reappraisal of the Hernia of Morgagni. Surgery 55 : 495-499, 1964.
PubMed
3) Al-Salem AH, et al : Congenital Morgagni's hernia : a national multicenter study. J Pediatr Surg 49 : 503-507, 2014.
PubMed
4) Golden J, et al : Pediatric Morgagni diaphragmatic hernia : a descriptive study. Pediatr Surg Int 33 : 771-775, 2017.
PubMed
5) Al-Salem AH : Congenital hernia of Morgagni in infants and children. J Pediatr Surg 42 : 1539-1543, 2007.
 
6) Marin J, Lopoo J : An infant with trisomy 21 and tachypnea. Pediatr Emerg Care 22 : 170-172, 2006.
PubMed
7) Shah P, et al : A symptolnatic morgagni hernia in a neonate. J Pediatr 140 : 466, 2002.
 
8) Matsui H, et al : Transhepatic diaphragm echography for diaphragm paralysis in infants. Intensive Care Med 41 : 523-524, 2015.
PubMed
9) Georgacopulo P, et al : Morgagni-Larrey hernia correction by laparoscopic surgery. Eur J Pediatr Surg 7 : 241-242, 1997.
PubMed
10) Alqahtani A, Al-Salem AH : Laparoscopic-assisted versus open repair of Morgagni hernia in infants and children. Surg Laparosc Endosc Percutan Tech 21 : 46-49, 2011.
PubMed
P.379 掲載の参考文献
1) 吉田雄一, ほか : 神経線維腫症1型 (レックリングハウゼン病) 診療ガイドライン 2018. 日本皮膚科学会雑誌 128 : 17-34, 2018.
 
2) Trovo-Marqui AB, Tajara EH : Neurofibromin : a generala general outlook. Clin Genet 70 : 1-13, 2006.
 
3) Gottfried ON, et al : Neurofibromatosis type 1 and tumorigenesis : molecular mechanisms and therapeutic implications. Neurosurg Focus 28 : E8, 2010.
PubMed
4) Friedman JM, et al : Cardiovascular disease in neurofibromatosis 1 : report of the NF1 Cardiovascular Task Force. Genet Med 4 : 105-111, 2002.
PubMed
5) 嶋田喜文, ほか : 神経線維腫症I型に合併した肋間動脈破裂の一例. 日本呼吸器外科学会雑誌 29 : 775-780, 2015.
 
6) Hirabaru K, Matsuo M : Neurological comorbidity in children with neurofibromatosis type 1. Pediatr Int 60 : 70-75, 2018.
PubMed
7) Durrani AA, et al : Modulation of spinal deformities in patients with neurofibromatosis type 1. Spine (Phila Pa 1976) 25 : 69-75, 2000.
PubMed
8) Winter RB, et al : Spine deformity in neurofibromatosis. A review of one hundred and two patients. J Bone Joint Surg Am 61 : 677-694, 1979.
PubMed
9) Yamaguchi M, et al : Surgical treatment of neurogenic tumors of the chest. Ann Thorac Cardiovasc Surg 10 : 148-151, 2004.
PubMed
10) Evans DG, et al : Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39 : 311-314, 2002.
PubMed
11) Niimura M : Neurofibromatosis in Japan. In : Tuberous Sclerosis and Neurofibromatosis : Epidemiology, Pathophysiology, Biology and Management (ed by Ishibashi Y, Hori Y), p22-31, Excerpta Medica, Elsevier Science Publication, Amsterdam, 1990.
 
12) Ueda K, et al : Computed tomography (CT) findings in 88 neurofibromatosis 1 (NF1) patients : Prevalence rates and correlations of thoracic findings. Eur J Radiol 84 : 1191-1195, 2015.
PubMed
13) Zamora AC, et al : Neurofibromatosis-associated lung disease : a case series and literature review. Eur Respir J 29 : 210-214, 2007.
PubMed
14) Oikonomou A, et al : HRCT findings in the lungs of non-smokers with neurofibromatosis. Eur J Radiol 80 : e520-523, 2011.
PubMed
15) Burkhalter JL, et al : Diffuse interstitial lung disease in neurofibromatosis. South Med J 79 : 944-946, 1986.
PubMed
16) Massaro D, Katz S : Fibrosing alveolitis : its occurrence, roentgenographic, and pathologic features in von Recklinghausen's neurofibromatosis. Am Rev Respir Dis 93 : 934-942, 1966.
 
17) Micera A, et al : Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci U S A 98 : 6162-6167, 2001.
PubMed
18) Reviron-Rabec L, et al : Pulmonary complications of type 1 neurofibromatosis. Rev Mal Respir 33 : 460-473, 2016.
PubMed
19) Walker L, et al : A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 95 : 233-238, 2006.
 
20) Furukawa K, et al : Novel mutations of neurofibromatosis type 1 gene in small cell lung cancers. Surg Today 33 : 323-327, 2003.
PubMed
21) Jutant EM, et al : Pulmonary hypertension associated with neurofibromatosis type 1. Eur Respir Rev 27 : 180053, 2018.
PubMed
22) Webb WR, et al : Fibrosing alveolitis in patients with neurofibromatosis. Radiology 122 : 289-293, 1977.
PubMed
23) Johannessen CM, et al : The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102 : 8573-8578, 2005.
PubMed
24) Weiss B, et al : Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas : a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol 17 : 596-603, 2015.
PubMed
25) Zehou O, et al : Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas : Results from a Phase 2a Trial. J Invest Dermatol 139 : 718-720, 2019.
 
26) Ferner RE, Gutmann DH : International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62 : 1573-1577, 2002.
PubMed
27) Levi AD, et al : The surgical management of symptomatic peripheral nerve sheath tumors. Neurosurgery 66 : 833-840, 2010.
PubMed
28) Kolberg M, et al : Survival meta-analyses for > 1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 15 : 135-147, 2013.
PubMed
29) Fischer-Huchzermeyer S, et al : MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro. PLoS One 12 : e0187700, 2017.
PubMed
30) Madden JR, et al : Radiation-induced gliomas in 2 pediatric patients with neurofibromatosis type 1 : case study and summary of the literature. J Pediatr Hematol Oncol 36 : e105-108, 2014.
PubMed
31) Yokoyama A, et al : Distal acinar emphysema and interstitial pneumonia in a patient with von Recklinghausen's disease : five-year observation following quitting smoking. Intern Med 36 : 413-416, 1997.
 
P.383 掲載の参考文献
1) Whipple GH : A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissue. Bull Johns Hopkins Hosp 18 : 382-391, 1907.
 
2) Relman DA, et al : Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 327 : 293-301, 1992.
PubMed
3) Ramzan NN, et al : Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med 126 : 520-527, 1997.
PubMed
4) Raoult D, et al : Cultivation of the bacillus of Whipple's disease. N Engl J Med 342 : 620-625, 2000.
PubMed
5) Dolmans RA, et al : Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections. Clin Microbiol Rev 30 : 529-555, 2017.
PubMed
6) Schneider T, et al : Whipple's disease : new aspects of pathogenesis and treatment. Lancet Infect Dis 8 : 179-190, 2008.
PubMed
7) Urbanski G, et al : Whipple disease revealed by lung involvement : a case report and literature review. Chest 141 : 1595-1598, 2012.
PubMed
8) Bassene H, et al : Tropheryma whipplei as a Cause of Epidemic Fever, Senegal, 2010-2012. Emerg Infect Dis 22 : 1229-1334, 2016.
PubMed
9) Lagier JC, et al : Tropheryma whipplei DNA in bronchoalveolar lavage samples : a case control study. Clin Microbiol Infect 22 : 875-879, 2016.
PubMed
10) Li W, et al : Severe pneumonia in adults caused by Tropheryma whipplei and Candida sp. Infection : a 2019 case series. BMC Pulm Med 21 : 29, 2021.
PubMed
11) Yogi T, et al : Whipple's disease : the first Japanese case diagnosed by electron microscopy and polymerase chain reaction. Intern Med 43 : 566-570, 2004.
PubMed
12) Tatsuki M, et al : Whipple disease mimicking inflammatory bowel disease. Intest Res 19 : 119-125, 2021.
 
13) Lagier JC, et al : Systemic Tropheryma whipplei : clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine (Baltimore) 89 : 337-345, 2010.
PubMed
14) Edouard S, et al : The rise of Tropheryma whipplei : a 12-year retrospective study of PCR diagnoses in our reference center. J Clin Microbiol 50 : 3917-3920, 2012.
 
15) Hokama A, et al : Tropheryma whipplei : an unusual cause of the accumulation in positron emission tomography. Clin Microbiol Infect, 2020. [DOI : 10.1016/j.cmi.2020.12.012]
 
P.386 掲載の参考文献
1) Rappaport H : Tumors of the hematopoietic system. In : Atlas of Tumor Pathology, p49-63, Armed Forces Institute of Pathology, Washington DC, 1966.
 
2) Wilson MS, et al : Malignant histiocytosis. A reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies. Cancer 66 : 530-536, 1990.
PubMed
3) Egeler RM, et al : Malignant histiocytosis : a reassessment of cases formerly classified as histiocytic neoplasms and review of the literature. Med Pediatr Oncol 25 : 1-7, 1995.
PubMed
4) 定平吉都, ほか : Virus-associated hemophagocytic syndrome. 病理と臨床 21 (増刊) : 67-72, 2003.
 
5) Weiss LM, et al : Histiocytic sarcoma. In : WHO Classification of Tumours, revised 4th ed, Vol 2, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p468-470, IARC Press, Lyon, 2017.
 
6) Hanson CA, et al : True histiocytic lymphoma : histopathologic, immunophenotypic and genotypic analysis. Br J Haematol 73 : 187-198, 1989.
PubMed
7) Takahashi E, et al : Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53 : 1-8, 2013.
PubMed
8) 前田邦彦, ほか : 組織球ならびに樹状細胞腫瘍. 最新・悪性リンパ腫アトラス (菊池昌弘, 森茂郎編), p299-309, 文光堂, 2004.
 
9) Feldman AL, et al : Histiocytic sarcoma after acute lymphoblastic leukaemia : a common clonal origin. Lancet Oncol 5 : 248-250, 2004.
PubMed
10) Hornick JL, et al : Extranodal histiocytic sarcoma : clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol 28 : 1133-1144, 2004.
PubMed
11) 牧島秀樹, 北野喜良 : 蛋白漏出性胃腸症と汎血球減少症を合併した脾臓原発組織球性肉腫の1例. 日本リンパ網内系学会会誌 40 : 205-210, 2000.
 
12) 岡田貴典, ほか : 脾原発組織球性肉腫の1剖検例. 松山赤十字病院医学雑誌 29 : 43-49, 2004.
 
13) Kumamoto T, et al : A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib. Int J Hematol 109 : 228-232, 2019.
PubMed
14) Gounder MM, et al : Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. N Engl J Med 378 : 1945-1947, 2018.
PubMed
15) Sato N, et al : Primary cutaneous localized/clearly-outlined true histiocytic sarcoma : Two long-term follow-up cases. J Dermatology 47 : 651-653, 2020.
 
P.393 掲載の参考文献
1) Yankauer S : Benign tumor of bronchus. Laryngoscope 39 : 549-551, 1929.
 
2) Caldarola VT, et al : Benign Tumors Tumorlike Conditions of the Trache and Bronchi. Ann Otol Rhinol Laryngol 73 : 1042-1061, 1964.
PubMed
3) 野畑浩一, ほか : 悪性腫瘍との鑑別を要した気管炎症性ポリープの1例. 気管支学 21 : 349-353, 1999.
Medical*Online
4) Jackson C, Jackson CL : Benign tumors of the trachea and bronchi : with especial reference to tumor-like formations of inflammatory origin. JAMA 99 : 1747-1754, 1932.
 
5) Tedeschi LG, et al : Endobronchial polyp. Chest 63 : 110-112, 1973.
PubMed
6) SALEK J, et al : Solitary bronchial polyps of inflammatory origin ; a report of two cases treated by operation. J Thorac Surg 35 : 807-815, 1958.
PubMed
7) 山口悦郎, ほか : 気道の炎症性ポリープ-51例の特発例の文献的考察を中心に-. 気管支学 6 : 163-171, 1984.
 
P.397 掲載の参考文献
1) Vignes S, Baran R : Yellow nail syndrome : a review. Orphanet J Rare Dis 12 : 42, 2017.
PubMed
2) Maldonado F, et al : Yellow nail syndrome : analysis of 41 consecutive patients. Chest 134 : 375-381, 2008.
PubMed
3) Piraccini BM, et al : Yellow nail syndrome : clinical experience in a series of 21 patients. J Dtsch Dermatol Ges 12 : 131-137, 2014.
 
4) Yalcin E, et al : Yellow nail syndrome in an infant presenting with lymphedema of the eyelids and pleural effusion. Clin Pediatr (Phila) 43 : 569-572, 2004.
 
5) Samman PD, White WF : The "Yellow Nail" Syndrome. Br J Dermatol 76 : 153-157, 1964.
PubMed
6) Emerson PA : Yellow nails, lymphoedema, and pleural effusions. Thorax 21 : 247-253, 1966.
PubMed
7) Hiller E, et al : Pulmonary manifestations of the yellow nail syndrome. Chest 61 : 452-458, 1972.
PubMed
8) Hoque SR, et al : Yellow nail syndrome : not a genetic disorder? Eleven new cases and a review of the literature. Br J Dermatol 156 : 1230-1234, 2007.
PubMed
9) Liptrot S, et al : Early pulmonary manifestations of yellow nail syndrome : a case report. Virchows Arch 451 : 985-986, 2007.
PubMed
10) Woodfield G, et al : Bronchiectasis in yellow nail syndrome. Respirology 22 : 101-107, 2017.
PubMed
11) Bull RH, et al : Lymphatic function in the yellow nail syndrome. Br J Dermatol 134 : 307-312, 1996.
PubMed
12) 田中宏幸, ほか : ブシラミンによる黄色爪症候群の1例. リウマチ科 35 : 309-313, 2006.
 
13) Lambert EM, et al : Yellow nail syndrome in three siblings : a randomized double-blind trial of topical vitamin E. Pediatr Dermatol 23 : 390-395, 2006.
PubMed
14) Tanaka E, et al : Implantation of a pleurovenous shunt for massive chylothorax in a patient with yellow nail syndrome. Thorax 60 : 254-255, 2005.
 
15) 桂浩, ほか : 難治性胸水に対する胸腔鏡補助下胸腔・腹腔シャント術の経験 : 黄色爪症候群症例の1例. 日本呼吸器外科学会雑誌 21 : 565-570, 2007.
 
P.401 掲載の参考文献
1) Kuehni CE, et al : Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J 36 : 1248-1258, 2010.
PubMed
2) Inaba A, et al : Primary ciliary dyskinesia in Japan : systematic review and meta-analysis. BMC Pulm Med 19 : 135, 2019.
 
3) Noone PG, et al : Discordant organ laterality in monozygotic twins with primary ciliary dyskinesia. Am J Med Genet 82 : 155-160, 1999.
PubMed
4) Balfour-Lynn IM, et al : Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 75 : 319-322, 1996.
PubMed
5) Nakano H, et al : Reduced nasal nitric oxide in diffuse panbronchiolitis. Am J Respir Crit Care Med 162 : 2218-2220, 2000.
PubMed
6) Hasegawa A, et al : A rare case of Young's syndrome in Japan. Intern Med 33 : 649-653, 1994.
PubMed
7) Lucas JS, et al : European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J 49 : 1601090, 2017.
PubMed
8) Shapiro AJ, et al : Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 197 : e24-e39, 2018.
PubMed
9) Barbato A, et al : Primary ciliary dyskinesia : a consensus statement on diagnostic and treatment approaches in children. Eur Respir J 34 : 1264-1276, 2009.
PubMed
10) Kobbernagel HE, et al : Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA) : a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 8 : 493-505, 2020.
PubMed
P.405 掲載の参考文献
1) Bellani G, et al : Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 315 : 788-800, 2016.
PubMed
2) Blum JM, et al : Preoperative and intraoperative predictors of postoperative acute respiratory distress syndrome in a general surgical population. Anesthesiology 118 : 19-29, 2013.
 
3) Canet J, et al ; ARISCAT Group : Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 113 : 1338-1350, 2010.
 
4) Kometani T, et al : Acute respiratory distress syndrome after pulmonary resection. Gen Thorac Cardiovasc Surg 61 : 504-512, 2013.
PubMed
5) Kutlu CA, et al : Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 69 : 376-380, 2000.
PubMed
6) Neto AS, et al : The LAS VEGAS risk score for prediction of postoperative pulmonary complications : An observational study. Eur J Anaesthesiol 35 : 691-701, 2018.
 
7) Craig SR, et al : Acute phase responses following minimal access and conventional thoracic surgery. Eur J Cardiothorac Surg 20 : 455-463, 2001.
PubMed
8) Collard CD, et al : Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 94 : 1133-1138, 2001.
PubMed
9) Slinger P : Post-pneumonectomy pulmonary edema : is anesthesia to blame? Curr Opin Anaesthesiol 12 : 49-54, 1999.
PubMed
10) Erdmann AJ, et al : Effect of increased vascular pressure on lung fluid balance in unanesthetized sheep. Circ Res 37 : 271-284, 1975.
PubMed
11) Michelet P, et al : Protective ventilation influences systemic inflammation after esophagectomy : a randomized controlled study. Anesthesiology 105 : 911-919, 2006.
PubMed
12) Choi G, et al : Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 105 : 689-695, 2006.
PubMed
13) ARDS診療ガイドライン 2016 (3学会合同ARDS診療ガイドライン2016作成委員会編), 総合医学社, 2016.
 
14) National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, et al : Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354 : 2564-2575, 2006.
PubMed
15) Ibrahim EH, et al : Early versus late enteral feeding of mechanically ventilated patients : results of a clinical trial. JPEN J Parenter Enteral Nutr 26 : 174-181, 2002.
PubMed
16) Meduri GU, et al : Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial. Chest 131 : 954-963, 2007.
PubMed
17) Villar J, et al : Dexamethasone treatment for the acute respiratory distress syndrome : a multicentre, randomised controlled trial. Lancet Respir Med 8 : 267-276, 2020.
PubMed
18) Ball L, et al : Postoperative respiratory disorders. Curr Opin Crit Care 22 : 379-385, 2016.
PubMed
P.409 掲載の参考文献
1) 田坂皓 : 胸部X線読影テキスト [改訂第2版], 文光堂, 1980.
 
2) 久保武 : わかりやすい胸部画像診断-胸部X線をどう見るか. 日本呼吸ケア・リハビリテーション学会誌 25 : 180-185, 2015.
 
3) Fraser RG, et al : Lung diseases that decrease roentgenographic density. In : Diagnosis of Diseases of the Chest, 3rd ed, Vol 1, p639-663, WB Saunders, Philadelphia, 1989.
 
4) 長石忠三, ほか : 肺気腫様陰影. 胸部の異常陰影 [全改訂3版] -X線による鑑別診断-, p356-363, 金芳堂, 1983.
 
5) 新野稔 : 肺の透過性亢進と不透明肺. 胸部X線診断の基礎知識, p166-167, 医学書院 1987.
 
6) 鰤岡直人, 清水英治 : 禁煙. 最新医学別冊 診断と治療の新ABC呼吸器腫瘍, p203-212, 最新医学社, 2017.
 
7) Swyer PR, James GC : A case of unilateral pulmonary emphysema. Thorax 8 : 133-136, 1953.
PubMed
8) 中村武博, ほか : Swyer-James症候群について. 呼吸 26 : 1035-1038, 2007.
Medical*Online
9) 相澤久道 : Swyer-James症候群. フレイザー 呼吸器病学エッセンス (清水英治, 藤田次郎監訳), p761-763, 西村書店, 2009.
 
10) 斎藤朋子 : Swyer-James症候群. 小児科診療 79 (Suppl) : 173, 2016.
 
11) Poland A : Deficiency of the pectoral muscles. Guy's Hosp Rep 6 : 191-193, 1841.
 
12) 川崎一輝, 遠藤美紀 : Poland症候群 ; 縦隔疾患. 胸壁, 胸郭, 横隔膜異常, その他疾患. 別冊日本臨牀新領域別症候群シリーズ No. 10 呼吸器症候群 (第2版) III, p560-562, 日本臨牀社, 2009.
 
13) 遠藤美紀, ほか : Poland症候群における小児期の呼吸障害. 日本小児呼吸器疾患学会雑誌 16 : 115-118, 2005.
Medical*Online
P.414 掲載の参考文献
1) Shaw RR : Mucoid impaction of the bronchi. J Thorac Surg 22 : 149-163, 1951.
PubMed
2) Hutcheson JB, et al : Mucoid impaction of the bronchi. Am J Clin Pathol 33 : 427-432, 1960.
PubMed
3) Katzenstein AL, et al : Bronchocentric granulomatosis, mucoid impaction, and hypersensitivity reactions to fungi. Am Rev Respir Dis 111 : 497-537, 1975.
PubMed
4) Bronchial Disorders : Mucoid impaction of bronchi : Allergic bronchopulmonary fungal disease ; Plastic bronchitis. In : ATLAS of Nontumor Pathology, Fascicle 2, Non-Neoplastic Disorders of the Lower Respiratory Tract (ed by Travis WD, et al), p412-421, American Registry of Pathology and the Armed Forces Institute of Pathology, Washington DC, 2002.
 
5) Dunican EM, et al : Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest 128 : 997-1009, 2018.
PubMed
6) Ueki S, et al : Eosinophil extracellular trap cell death-derived DNA traps : Their presence in secretions and functional attributes. J Allergy Clin Immunol 137 : 258-267, 2016.
PubMed
7) Rubin BK : Plastic Bronchitis. Clin Chest Med 37 : 405-408, 2016.
PubMed
8) Yoshida M, et al : Eosinophil extracellular traps in the casts of plastic bronchitis associated with influenza virus infection. Chest, 2021. (DOI : 10.1016/j.chest.2021.05.001)
 
9) Oguma T, et al : Allergic bronchopulmonary aspergillosis in Japan : A nationwide survey. Allergol Int 67 : 79-84, 2018.
PubMed
10) Muniz VS, et al : Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus. J Allergy Clin Immunol 141 : 571-585. e7, 2018.
 
11) Kraemer R, et al : Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 174 : 1211-1220, 2006.
PubMed
12) Logan PM, et al : High-attenuation mucous plugging in allergic bronchopulmonary aspergillosis. Can Assoc Radiol J 47 : 374-377, 1996.
PubMed
13) Asano K, et al : New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol 147 : 1261-1268. e5, 2021.
 
14) Shah A, et al : Allergic Bronchopulmonary Aspergillosis : A Perplexing Clinical Entity. Allergy Asthma Immunol Res 8 : 282-297, 2016.
PubMed
15) Wark P, et al : Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization. J Allergy Clin Immunol Pract 8 : 3428-3433. e1, 2020.
 
P.418 掲載の参考文献
1) 三好和夫, ほか : 人体におけるAdjuvant加遷延感作を思わせる高γグロブリン血症-乳房形成術の後にみられた障害-. 日本医事新報 2122 : 9-14, 1964.
 
2) Kumagai Y, et al : Scleroderma after cosmetic surgery : four cases of human adjuvant disease. Arthritis Rheum 22 : 532-537, 1979.
PubMed
3) 熊谷安夫 : ヒトアジュバント病の臨床的意義. 臨床免疫 21 : 726-737, 1989.
 
4) Shoenfeld Y, et al : 'ASIA' -autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 36 : 4-8, 2011.
PubMed
5) Pearson CM : Experimental joint disease. Observations on adjuvant-induced arthritis. J Chronic Dis 16 : 863-874, 1963.
PubMed
6) Janowsky EC, et al : Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 342 : 781-790, 2000.
PubMed
7) Press RI, et al : Antinuclear autoantibodies in women with silicone breast implants. Lancet 340 : 1304-1307, 1992.
PubMed
8) Lappe MA : Silicone-reactive disorder : a new autoimmune disease caused by immunostimulation and superantigens. Med Hypotheses 41 : 348-352, 1993.
PubMed
9) Domanskis EJ, Owsley JQ Jr : Histological investigation of the etiology of capsule contracture following augmentation mammaplasty. Plast Reconstr Surg 58 : 689-693, 1976.
 
10) Baldwin CM, et al : Silicone-induced human adjuvant disease? Ann Plast Surg 10 : 270-273, 1983.
PubMed
11) Kumagai Y, et al : Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum 27 : 1-12, 1984.
 
12) Chang KC, et al : Cutaneous and pulmonary sarcoidosis in a Hong Kong Chinese woman with silicone breast prostheses. Respirology 8 : 379-382, 2003.
 
13) Oishi T, et al : A case of Human adjuvant disease complicated with sarcoidosis. The Journal of the Japan Society for Respiratory Endoscopy 42 : 369-374, 2020.
 
14) 池田政輝, 千田金吾 : アジュバント病としてのサルコイドーシス. 日本胸部臨床 72 : 866-874, 2013.
Medical*Online
15) Pernis B, et al : Adjuvant effect of silica (tridymite) on antibody production. Proc Soc Exp Biol Med 110 : 390-392, 1962.
PubMed

書評

最近チェックした商品履歴

Loading...